clavulanic acid profile

Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

clavulanate : The conjugate base of clavulanic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5280980
CHEMBL ID	777
CHEBI ID	48947
SCHEMBL ID	6093
SCHEMBL ID	34260
MeSH ID	M0029416

Synonym
brn 0787059
acido clavulanico [inn-spanish]
3008-b
acide clavulanique [inn-french]
brl-14151
brl 14151
acidum clavulanicum [inn-latin]
4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2r-(2alpha,3z,5alpha))
(z)-(2r,5r)-3-(2-hydroxyethyliden)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptan-2-carbonsaeure
clavulansaeure [inn]
4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2r-(2-alpha,3z,5-alpha))-
einecs 261-069-2
clavulox (tn)
clavulanic acid (inn)
D07711
BSPBIO_002430
clavulonic acid
acide clavulanique
mm 14151
acido clavulanico
antibiotic mm 14151
CHEBI:48947 ,
acidum clavulanicum
clavulansaeure
clavulanic acid
C06662
clavulanate
(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
clavulinic acid
(z)-(2r,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
DB00766
rx-10100
serdaxin
CHEMBL777 ,
bdbm50021959
NCGC00188985-01
brl14151
clavulanate lithium
AKOS016009164
clavulanic acid [inn:ban]
unii-23521w1s24
23521w1s24 ,
EPITOPE ID:117130
(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
clavulanic acid [mi]
clavulanic acid [inn]
clavulanic acid [who-dd]
4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2r-(2.alpha.,3z,5.alpha.))-
clavulanic acid [mart.]
clavulanate [vandf]
SCHEMBL6093
SCHEMBL34260
4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2r,3z,5r)-
DTXSID2022830 ,
gtpl11128
SBI-0206779.P001
clavulox
4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,3-(2-hydroxyethylidene)-7-oxo-,(2r,3z,5r)-
Q415709
1365254-41-6
MS-23077
HY-A0256
CS-0017600
clavulanateacid
EN300-7431555
66428-09-9
clavulansaure
dtxcid702830
acidum clavulanicum (inn-latin)
4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2r-(2alpha,3z,5alpha))-
clavulanic acid (mart.)

Excerpt	Reference	Relevance
" Adverse reactions to the study drug were minimal; eosinophilia, unaccompanied by other allergic phenomena, and oral candidiasis were most frequent."	( Clinical trial of the efficacy and safety of ticarcillin and clavulanic acid. Bibler, M; Bode, R; Bullock, WE; Douce, R; Hamilton, B; Roselle, GA; Staneck, JL; Sullivan, R, 1985)	0.27
" Adverse reactions (all reversible) were reported in 11 (61 percent) patients, the most frequent of which was phlebitis."	( Safety and effectiveness of ticarcillin plus clavulanic acid in the treatment of community-acquired acute pyelonephritis in adult women. Aldridge, KE; Derks, FW; Marier, RL; Martin, DH; Sanders, CV, 1985)	0.27
" Adverse drug-related reactions required discontinuation of treatment in two patients, although other minor abnormal laboratory findings were common."	( Safety and efficacy of ticarcillin plus clavulanic acid in the treatment of infections of soft tissue, bone, and joint. Finegold, SM; George, WL; Helsel, CL; Johnson, CC; Mulligan, ME; Reinhardt, JF; Terpenning, MS; Wallace, SL, 1985)	0.27
" All 43 patients were monitored for adverse reactions by both clinical observation and laboratory tests."	( Safety and effectiveness of ticarcillin plus clavulanate potassium in treatment of lower respiratory tract infections. Mostow, SR; O'Brien, RF, 1985)	0.27
" The incidence of adverse reactions was similar in both groups."	( Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections. File, TM; Tan, JS, 1994)	0.29
" We conclude that clarithromycin is a safe and effective antimicrobial agent for the treatment of acute otitis media in children."	( Comparative study of the safety and efficacy of clarithromycin and amoxicillin-clavulanate in the treatment of acute otitis media in children. Aronoff, S; Arrieta, A; Aspin, MM; Hoberman, A; Lang, DJ; McCarty, J; McLinn, SE, 1994)	0.29
" Gastrointestinal adverse events were the most commonly reported in both groups."	( Comparative safety and efficacy of clarithromycin and amoxicillin/clavulanate in the treatment of acute otitis media in children. McCarty, JM; Phillips, A; Wiisanen, R, 1993)	0.29
" We conclude that OM-85-BV is safe at pediatric ages, as well as accelerates the cure and improvement of subacute sinusitis while it lowers the incidence of respiratory infections."	( [Safety and efficacy of OM-85-BV plus amoxicillin/clavulanate in the treatment of subacute sinusitis and the prevention of recurrent infections in children]. Alvarez, A; Berber, A; De la Torre, C; Faure, A; Gómez Barreto, D, )	0.13
"5%) and also the incidence of adverse events which occurred in 24/163 (14."	( Comparison of the efficacy and safety of a short course of ceftibuten with that of amoxycillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. Guest, N; Langan, CE, 1998)	0.3
" Comparable incidences of adverse events, mainly mild or moderate in intensity, were experienced in each treatment group."	( Treatment of complicated intra-abdominal infections: comparison of the tolerability and safety of intravenous/oral trovafloxacin versus intravenous imipenem/cilastatin switching to oral amoxycillin/clavulanic acid. Luke, DR; Peterson, J, )	0.13
" In spite of statements about the safe use of drugs in lactation by the American Academy of Pediatrics, medical professionals remain confused regarding the management of drug therapy in nursing mothers, and this can lead to suboptimal prescribing and poor compliance."	( The safety of amoxicillin/clavulanic acid and cefuroxime during lactation. Benyamini, L; Berkovitch, M; Bortnik, O; Braunstein, R; Bulkowstein, M; Merlob, P; Stahl, B; Zimmerman, D, 2005)	0.33
" It is well documented that the clavulanate component may cause adverse reactions by itself, thus exposing patients to further, and sometimes undue, risks."	( Amoxicillin and amoxicillin plus clavulanate: a safety review. Caputi, AP; De Sarro, A; Polimeni, G; Salvo, F, 2009)	0.35
" Adverse event rates were comparable between treatment groups."	( Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. Amábile-Cuevas, CF; Arvis, P; Bogner, JR; Cruz-Alcázar, J; Hernández-Oliva, G; Reimnitz, P; Vick-Fragoso, R, 2009)	0.35
"Antibiotics for suspected acute appendicitis are safe and effective and may avoid unnecessary appendectomy, reducing operation rate, surgical risks, and overall costs."	( The NOTA Study (Non Operative Treatment for Acute Appendicitis): prospective study on the efficacy and safety of antibiotics (amoxicillin and clavulanic acid) for treating patients with right lower quadrant abdominal pain and long-term follow-up of conser Ansaloni, L; Biscardi, A; Catena, F; Coccolini, F; Di Saverio, S; Giorgini, E; Pisano, M; Sartelli, M; Sibilio, A; Smerieri, N; Tugnoli, G; Villani, S, 2014)	0.4
" Azithromycin was not associated with excess serious adverse events (SAEs)."	( Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. Butler-Laporte, G; Menzies, D; Winters, N, 2015)	0.42
" Only six cases reported adverse events attributable to meropenem/clavulanate (four of them then restarting treatment)."	( Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Abdo Arbex, M; Akkerman, OW; Alarcon Arrascue, E; Alarcon Guizado, V; Aleska, A; Alffenaar, JW; Avchinko, V; Bonini, EH; Caminero, JA; Centis, R; Chong Marín, FA; Collahuazo López, L; D'Ambrosio, L; De Lorenzo, S; de Vries, G; Dore, S; Gaga, M; Gualano, G; Kunst, H; Matteelli, A; Migliori, GB; Moschos, C; Palmieri, F; Papavasileiou, A; Payen, MC; Roby Arias, AJ; Scardigli, A; Skrahina, A; Solovic, I; Sotgiu, G; Spanevello, A; Sulis, G; Tadolini, M; Tiberi, S; Vargas Vasquez, D; Viggiani, P; White, V; Zumla, A, 2016)	0.43
" While no adverse events were reported for IC, 2 minor side effects, only, were attributed to linezolid (17%); in both cases the drug was re-started without further problems."	( Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in Brazil. Arbex, MA; Bonini, EH; Centis, R; D'Ambrosio, L; Kawakame Pirolla, G; Migliori, GB, )	0.13
" When using amoxicillin/clavulanate in the elderly, the risk of adverse drug reaction may be greater."	( Multiple-dose pharmacokinetics and safety of amoxicillin/clavulanate in healthy elderly subjects. Choi, Y; Chung, JY; Jang, K; Lee, SW; Yoon, SH, 2020)	0.56
" Safety assessments including clinical laboratory tests, physical examination, vital signs, and adverse event (AE) monitoring were performed throughout the study."	( Multiple-dose pharmacokinetics and safety of amoxicillin/clavulanate in healthy elderly subjects. Choi, Y; Chung, JY; Jang, K; Lee, SW; Yoon, SH, 2020)	0.56
"5 mg was safe and well-tolerated, the systemic exposure of amoxicillin and clavulanate was higher in elderly subjects than in younger subjects."	( Multiple-dose pharmacokinetics and safety of amoxicillin/clavulanate in healthy elderly subjects. Choi, Y; Chung, JY; Jang, K; Lee, SW; Yoon, SH, 2020)	0.56
"An early intravenous-to-oral antibiotic switch with amoxicillin-clavulanic acid is non-inferior to a full course of intravenous antibiotics in neonates with probable bacterial infection and is not associated with an increased incidence of adverse events."	( Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiorit Allegaert, K; Baartmans, MGA; den Butter, PCP; Driessen, GJA; Eijkemans, M; Hartwig, NG; Heidema, J; Keij, FM; Kenter, S; Kornelisse, RF; Meijssen, CB; Norbruis, OF; Qi, H; Reiss, IKM; Stam-Stigter, GM; Tramper-Stranders, GA; van Beek, RHT; van Dalen-Vink, I; van den Berg, MM; van der Meer-Kappelle, LH; van der Sluijs-Bens, J; van Driel, A; van Rooij, LGM; van Rossem, MC; von Lindern, JS, 2022)	0.72

Excerpt	Reference	Relevance
" The elimination half-life of clavulanate in some individuals was much shorter because of higher plasma clearance."	( Pharmacokinetics of intravenous amoxycillin and potassium clavulanate in seriously ill children. Barnes, ND; Horton, R; Jones, AE; Tasker, TC, 1990)	0.28
" The pharmacokinetic parameters of the two components are similar, both being eliminated primarily by renal excretion."	( The pharmacokinetics of sultamicillin. Bruckner, G; Hampel, B; Koeppe, P; Lode, H, 1989)	0.28
" The mean values of total serum clearance, mean residence time, volume of distribution at steady state, and terminal half-life for amoxycillin on the non-dialysis day were 14."	( Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin. Boon, R; Davies, BE; Descoeudres, CE; Horton, R; Reubi, FC, 1988)	0.27
" This is supported by comparison of certain pharmacokinetic parameters for TICAR and CLA."	( Serum levels and pharmacokinetics of ticarcillin and clavulanic acid in dog following parenteral administration of Timentin. Garg, RC; Keefe, TJ; Vig, MM, 1987)	0.27
" Plasma data after intravenous administration were subjected to pharmacokinetic analysis using a two-compartment open model."	( Bioavailability and pharmacokinetics of clavulanic acid in healthy subjects. Clarke, JG; Coates, PE; Davies, BE; Sutton, JA; Thawley, AR, 1985)	0.27
" Model-dependent and noncompartmental pharmacokinetic parameters were congruous."	( Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis. Brown, AL; Jacobs, RF; Kearns, GL; Kluza, RB; Trang, JM; Underwood, FL; Warren, RH, 1985)	0.27
" Clavulanic acid is adequately absorbed after oral administration and its basic pharmacokinetic characteristics are similar to those of amoxycillin."	( Amoxycillin/clavulanic acid: a review of its antibacterial activity, pharmacokinetics and therapeutic use. Avery, GS; Brogden, RN; Carmine, A; Heel, RC; Morley, PA; Speight, TM, 1981)	0.26
"The pharmacokinetic behaviour of an amoxicillin/clavulanic acid combination was studied after intravenous administration of single doses (20 mg/kg per kg body weight) to five sheep and six goats."	( Comparative pharmacokinetics of amoxicillin/clavulanic acid combination after intravenous administration to sheep and goats. Baggot, JD; Carceles, CM; Escudero, E, 1995)	0.29
" After oral administration of both drugs their pharmacokinetic behaviour was best described by an open one-compartment model with first-order absorption."	( Pharmacokinetics of amoxicillin/clavulanic acid combination after intravenous and oral administration in goats. Carceles, CM; Carli, S; Escudero, E; Serrano, JM; Vicente, MS, 1995)	0.29
"The pharmacokinetic behaviour of an amoxicillin/clavulanic acid combination (25 mg kg-1), and both drugs alone (amoxicillin 20 mg kg-1), clavulanic acid 5 mg kg-1), was studied after intravenous (i."	( Pharmacokinetics of amoxicillin/clavulanic acid combination and of both drugs alone after intravenous administration to goats. Carceles, CM; Escudero, E; Vicente, S, 1996)	0.29
" After intramuscular administration both drugs had a significantly longer half-life (P<0."	( Pharmacokinetics of amoxicillin/clavulanic acid combination after intravenous and intramuscular administration to pigeons. Carceles, CM; Escudero, E; Vicente, MS, )	0.13
" The objective of this article is to evaluate the pharmacokinetic properties of three commercially available beta-lactamase inhibitors."	( Pharmacokinetic properties of beta-lactamase inhibitors. de la Pena, A; Derendorf, H, 1999)	0.3
"Based on published articles in the literature, the pharmacokinetic properties of the beta-lactamase inhibitors clavulanic acid, sulbactam and tazobactam are reviewed and compared."	( Pharmacokinetic properties of beta-lactamase inhibitors. de la Pena, A; Derendorf, H, 1999)	0.3
"When choosing combinations of a beta-lactam antibiotic with a beta-lactamase inhibitor, it is important to make sure that the pharmacokinetic properties of drug and inhibitor are similar and remain similar under changing pathophysiological conditions."	( Pharmacokinetic properties of beta-lactamase inhibitors. de la Pena, A; Derendorf, H, 1999)	0.3
"A randomized, open, single-dose, sinus tissue pharmacokinetic study with oral amoxicillin/clavulanic acid."	( Sinus tissue pharmacokinetics after oral administration of amoxicillin/clavulanic acid. Dinis, PB; Gomes, A; Martins, ML; Monteiro, MC; Silva, N, 2000)	0.31
"Although the in vitro activity of the tested drugs evaluated by time-kill curves seemed comparable, some pharmacokinetic and pharmacodynamic characteristics of TGA contribute to improving the resolution of the infective process."	( Comparative effect of thiamphenicol glycinate, thiamphenicol glycinate N-acetylcysteinate, amoxicillin plus clavulanic acid, ceftriaxone and clarithromycin on pulmonary clearance of Haemophilus influenzae in an animal model. De Vecchi, E; Drago, L; Fassina, MC; Gismondo, MR; Lombardi, A; Mombelli, B, )	0.13
"The enhanced pharmacokinetic profile of amoxicillin/clavulanate seen in this study suggests that this formulation is likely to be highly effective for the oral treatment of infections caused by bacteria--including beta-lactamase-producing organisms--and strains with amoxicillin MICs < or = 4 microg/mL."	( The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Allen, A; Bird, N; Davy, M; Dewit, O; Kaye, CM; McDonagh, M; Perry, S; Storm, K, 2001)	0.31
"To compare the pharmacodynamic effects of a pharmacokinetically enhanced formulation of amoxicillin 2000 mg twice daily, with amoxicillin 875 mg twice daily, 875 mg three times daily and 500 mg three times daily against Streptococcus pneumoniae with different susceptibility to amoxicillin in an in vitro kinetic model."	( Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens. Cars, O; Löwdin, E; Odenholt, I, 2004)	0.32
"The pharmacokinetic properties of amoxicillin and clavulanic acid when used alone or in combination are extensively reviewed and discussed in this article."	( New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review. Sánchez Navarro, A, 2005)	0.33
"We conducted a prospective pharmacokinetic study of oral co-amoxiclav in patients with melioidosis to determine the optimal dosage and dosing interval in this potentially fatal infection."	( Pharmacokinetic and pharmacodynamic assessment of co-amoxiclav in the treatment of melioidosis. Chaowagul, W; Chierakul, W; Dance, DA; Day, NP; Lindegardh, N; Maharjan, B; Peacock, SJ; Pongtavornpinyo, W; Short, JM; Singtoroj, T; Teparrukkul, P; Wangboonskul, J; White, NJ; Wuthiekanun, V, 2006)	0.33
" azithromycin once daily pharmacodynamic simulation was performed against 10(8) cfu/ml of four Streptococcus pneumoniae strains (exhibiting higher amoxicillin than penicillin MIC) and four Haemophilus influenzae strains: beta-lactamase producing, BLNAR (beta-lactamase-negative ampicillin-resistant) and BLPACR (beta-lactamase-positive amoxicillin/clavulanate-resistant)."	( Levofloxacin vs. azithromycin pharmacodynamic activity against S. pneumoniae and H. influenzae with decreased susceptibility to amoxicillin/clavulanic acid. Aguilar, L; Alou, L; Echeverría, O; Giménez, MJ; González, N; Martín, JE; Prieto, J; Sevillano, D; Torrico, M; Valdés, L, 2007)	0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" We present the first evaluation of the bone penetration of a beta-lactam by population pharmacokinetics and pharmacodynamic profiling via Monte Carlo simulations."	( Bone penetration of amoxicillin and clavulanic acid evaluated by population pharmacokinetics and Monte Carlo simulation. Bulitta, JB; Gusinde, J; Hennig, FF; Holzgrabe, U; Kinzig, M; Landersdorfer, CB; Sörgel, F, 2009)	0.35
" To date, there has been no report studying the pharmacokinetic characteristics of amoxicillin and clavulanic acid in man."	( Pharmacokinetics study of amoxycillin and clavulanic acid (8:1)--a new combination in healthy Chinese adult male volunteers using the LC-MS/MS method. Jia, Z; Men, X; Wang, R; Wang, Y; Xie, H; Xu, L; Zhang, J; Zhang, Q, 2013)	0.39
" Pharmacokinetic parameters of tablet (CDPX 200mg, CA 125mg) were evaluated."	( Simultaneous quantification of cefpodoxime proxetil and clavulanic acid in human plasma by LC-MS using solid phase extraction with application to pharmacokinetic studies. Dubala, A; George, R; Nagarajan, JS; Vimal, CS, 2013)	0.39
" However, the time required to reach maximum concentration at steady state and the elimination half-life were similar in the two age groups."	( Multiple-dose pharmacokinetics and safety of amoxicillin/clavulanate in healthy elderly subjects. Choi, Y; Chung, JY; Jang, K; Lee, SW; Yoon, SH, 2020)	0.56
"Prospective, single-centre, open-label, non-randomized, crossover pharmacokinetic trial having enrolled obese otherwise healthy adult subjects."	( Population pharmacokinetics and dosing simulations of amoxicillin in obese adults receiving co-amoxiclav. Burdet, C; Carette, C; Crémieux, AC; Czernichow, S; Duval, X; El-Helali, N; Hammas, K; Massias, L; Mellon, G; Mentré, F, 2020)	0.56
" Amoxicillin Cmax after oral administration significantly reduced with weight (P = 0."	( Population pharmacokinetics and dosing simulations of amoxicillin in obese adults receiving co-amoxiclav. Burdet, C; Carette, C; Crémieux, AC; Czernichow, S; Duval, X; El-Helali, N; Hammas, K; Massias, L; Mellon, G; Mentré, F, 2020)	0.56
" Here, we propose to estimate the in vivo functional ontogeny of transporters using a combined population pharmacokinetic (popPK) and physiology-based pharmacokinetic (PBPK) modeling approach called popPBPK."	( Estimation of Ontogeny Functions for Renal Transporters Using a Combined Population Pharmacokinetic and Physiology-Based Pharmacokinetic Approach: Application to OAT1,3. Allegaert, K; Cristea, S; De Cock, P; de Jaeger, A; De Paepe, P; Knibbe, CAJ; Krekels, EHJ, 2021)	0.62
" We included all published studies reporting pharmacokinetic data on clavulanic acid in neonates and children 0-18 years of age."	( Pharmacokinetics of Clavulanic Acid in the Pediatric Population: A Systematic Literature Review. Allegaert, K; Keij, FM; Koch, BCP; Kornelisse, RF; Muller, AE; Reiss, IKM; Tramper-Stranders, GA, 2022)	0.72
" Model-based pharmacokinetic studies that address both maturational and disease-specific changes in the pediatric population are therefore needed."	( Pharmacokinetics of Clavulanic Acid in the Pediatric Population: A Systematic Literature Review. Allegaert, K; Keij, FM; Koch, BCP; Kornelisse, RF; Muller, AE; Reiss, IKM; Tramper-Stranders, GA, 2022)	0.72
" WinNonlin software was used to evaluate the pharmacokinetic parameters (noncompartmental model)."	( Pharmacokinetics of Amoxicillin and Clavulanate Potassium for Suspension (200 mg/28.5 mg) in Healthy Subjects: Sample Add Stabilizer Study and Food Effects. Qin, F; Xu, PS; Xu, SM; Zhang, YD, 2022)	0.72

Excerpt	Reference	Relevance
"The activity of clavulanic acid alone and in combination with penicillin, amoxycillin, and carbenicillin was studied."	( In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin. Andrews, JM; Bedford, KA; Wise, R, 1978)	0.26
" Clavulanic acid at a concentration of 10 mg/l bound to PBP 2 by greater than 50% in all strains, and when combined with cefpirome, the density of PBP 2a was also reduced but not completely abolished."	( Activity of cefpirome combined with beta-lactamase inhibitors and affinity for the penicillin-binding proteins of methicillin-resistant Staphylococcus aureus. Griggs, DJ; Piddock, LJ; Traynor, EA, 1992)	0.28
"Amoxicillin, a beta-lactam antibiotic, was tested for its effect in combination with clavulanic acid, a beta-lactamase inhibitor, against 9 species of bacteria isolated from clinical specimens."	( Antibacterial activities of amoxicillin alone and in combination with clavulanic acid correlated with beta-lactamase production. Chang, SC; Hsieh, WC; Hsu, LY; Luh, KT, 1991)	0.28
"The beta-lactamase inhibitor, clavulanic acid, was combined with amoxicillin and with ticarcillin for in vitro studies with 586 staphylococci: 97 stock cultures of oxacillin-resistant strains recovered before 1982, and 489 blood or wound isolates collected from 40 separate medical centers during 1987-1988 (300 were oxacillin resistant)."	( Antistaphylococcal activity of amoxicillin and ticarcillin when combined with clavulanic acid. Evaluation of oxacillin-resistant and oxacillin-susceptible isolates. Barry, AL, )	0.13
"We evaluated cefotaxime (CTX) alone and in combination with its metabolite, desacetylcefotaxime (dCTX) against strains of Staphylococcus aureus that produce the four recognized variants of staphylococcal beta-lactamase and a beta-lactamase-producing isolate characterized by the expression of borderline resistance to methicillin."	( Evaluation of cefotaxime alone and in combination with desacetylcefotaxime against strains of Staphylococcus aureus that produce variants of staphylococcal beta-lactamase. Eades, SC; Kernodle, DS; Stratton, CW; Weeks, LS, )	0.13
"The in vitro synergistic activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam, combined with ampicillin, ticarcillin, mezlocillin, azlocillin, piperacillin, and apalcillin, were determined against 34 strains of members of the Enterobacteriaceae family, Pseudomonas aeruginosa, Aeromonas hydrophila, and Haemophilus influenzae with characterized plasmid or chromosomal beta-lactamases or both."	( Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Aronoff, SC; Jacobs, MR; Johenning, S; Shlaes, DM; Yamabe, S, 1986)	0.27
"The in-vitro synergistic activity of YTR 830, a new beta-lactamase inhibitor, combined with four extended-spectrum penicillins (ticarcillin, piperacillin, mezlocillin and apalcillin) against ticarcillin-resistant clinical isolates of Gram-negative enteric bacilli was compared with that of clavulanate and sulbactam."	( Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads. Aronoff, SC; Jacobs, MR; Johenning, S; Yamabe, S, 1986)	0.27
"The in vitro activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with six beta-lactams against 88 beta-lactamase-producing anaerobes were determined."	( Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes. Appelbaum, PC; Jacobs, MR; Spangler, SK; Yamabe, S, 1986)	0.27
"The in-vitro activity of a beta-lactamase inhibitor (clavulanic acid, sulbactam, BL-P2013 or BL-P2090) in combination with ampicillin against 13 isolates of Mycobacterium tuberculosis was determined by broth dilution."	( Comparison of four beta-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis. Cynamon, MH; Sorg, TB, 1987)	0.27
"The antibacterial activity of ampicillin against Enterobacteriaceae strongly increased when combined with 6 beta-bromopenicillanic acid (BPA) or clavulanic acid (CA)."	( In vitro activity of ampicillin alone and in combination with different concentrations of 6 beta-bromopenicillanic acid, clavulanic acid and mecillinam. Houben, AW; Stobberingh, EE; van Boven, CP, 1987)	0.27
" chelonei) to ticarcillin in combination with calvulanic acid (CA) was studied by the agar dilution method."	( In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium avium, Mycobacterium fortuitum, and Mycobacterium chelonae to ticarcillin in combination with clavulanic acid. Benavente, MC; Casal, MJ; Luna, MD; Rodriguez, FC, 1987)	0.27
" Four different groups of animals with appropriate controls were treated with penicillin or ticarcillin alone or in combination with CA."	( Activity of penicillin or ticarcillin in combination with clavulanic acid in the treatment of experimental intra-abdominal abscess. Bansal, MB; Prabahala, R; Thadepalli, H, 1986)	0.27
"Twelve strains of Nocardia asteroides were studied for their susceptibility to 21 beta-lactam antibiotics, alone or in combination with clavulanic acid, sulbactam, or BLP 2013, and for their content of beta-lactamase."	( In-vitro susceptibility of Nocardia asteroides to 21 beta-lactam antibiotics, in combination with three beta-lactamase inhibitors, and its relationship to the beta-lactamase content. Acar, JF; Gutmann, L; Kitzis, MD, 1985)	0.27
"To study the absorption and disposition of clavulanic acid, ten healthy men received one intravenous and one oral dose of 125 mg clavulanic acid in combination with amoxycillin."	( Pharmacokinetics of clavulanic acid, given in combination with amoxycillin, in volunteers. Fellner, H; Hedström, SA; Nilsson-Ehle, I; Nilsson-Ehle, P; Sjövall, J, 1985)	0.27
" Amoxycillin, clavulanic acid in combination with either amoxycillin or ticarcillin, temocillin and cloxacillin displaced bilirubin at concentrations much higher than those found clinically."	( Displacement of bilirubin from cord serum by sulphadimethoxine, amoxycillin, clavulanic acid in combination with either amoxycillin or ticarcillin, temocillin and cloxacillin. Davies, BE, 1985)	0.27
" Combined with amoxicillin, YTR 830 is a potentially useful agent for therapy of many bacterial infections."	( Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. Aronoff, SC; Jacobs, MR; Johenning, S; Yamabe, S, 1984)	0.27
"The in-vitro activity of ticarcillin in combination with clavulanic acid was compared with that of ticarcillin alone, piperacillin, cefotaxime and, where appropriate, other beta-lactams against a total of 301 recent clinical isolates and characterized beta-lactamase producers."	( Clavulanic acid in combination with ticarcillin: an in-vitro comparison with other beta-lactams. Clarke, AM; Zemcov, SJ, 1984)	0.27
" This study demonstrated the efficacy of penicillin and clavulanic acid in the treatment of infections caused by Bacteroides fragilis alone or in combination with beta-lactamase-producing aerobic bacteria."	( Antibiotic and clavulanic acid treatment of subcutaneous abscesses caused by Bacteroides fragilis alone or in combination with aerobic bacteria. Brook, I; Coolbaugh, JC; Walker, RI, 1983)	0.27
"The comparative in vitro activity of amoxicillin alone and in combination with clavulanic acid against 15 isolates of Mycobacterium tuberculosis was evaluated by broth dilution susceptibility testing."	( In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. Cynamon, MH; Palmer, GS, 1983)	0.27
"We compared responses to amoxicillin combined with clavulanic acid (ACA) with a cefaclor regimen in children with skin and soft tissue infections (impetigo and cellulitis) due to Staphylococcus aureus, Streptococcus pyogenes, and Haemophilus species."	( Amoxicillin combined with clavulanic acid for the treatment of soft tissue infections in children. Campos, JM; Fleisher, GR; Wilmott, CM, 1983)	0.27
"In vitro activity against 100 strains of Bacteroides fragilis of ticarcillin alone and combined with 4 or 8 mg of clavulanic acid was compared with those of cefoxitin, cefotaxime, ceftazidime, lamoxactam , ceftriaxone and metronidazole."	( [Comparative bacteriostatic activity of ticarcillin, alone and combined with clavulanic acid, 5 cephalosporins and metronidazole against 100 strains of Bacteroides fragilis]. Bebear, C; de Barbeyrac, B; Quentin, C, 1984)	0.27
" pneumophila activity was observed for ceftriaxone (32 micrograms/ml), piperacillin (32 micrograms/ml), tazobactam alone (16 micrograms/ml), clavulanate alone (2 micrograms/ml), or tazobactam in combination with ceftriaxone (ceftriaxone/tazobactam at 32/4 and 16/16 micrograms/ml) or piperacillin (32/4 micrograms/ml)."	( In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species. Edelstein, MA; Edelstein, PH, 1994)	0.29
" However, strains expressing class A beta-lactamase were susceptible to cefodizime in combination with clavulanic acid."	( In vitro activity of cefodizime (HR-221) in combination with beta-lactamase inhibitors. Amicosante, G; Franceschini, N; Oratore, A; Perilli, M; Segatore, B; Setacci, D, 1993)	0.29
" The MIC of amoxycillin in combination with clavulanic acid was > or =2 mg/L for 27/30 (90%) isolates."	( Susceptibility of multidrug-resistant strains of Mycobacterium tuberculosis to amoxycillin in combination with clavulanic acid and ethambutol. Abate, G; Miörner, H, 1998)	0.3
"The antimicrobial efficacies of beta-lactams alone and in combination with beta-lactamase inhibitors were investigated by applying a rabbit tissue cage model against a strain of Pseudomonas aeruginosa with an inducible AmpC (iAmpC) beta-lactamase."	( Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase. Li, C; Lister, PD; Nicolau, DP; Nightingale, CH; Quintiliani, R, 2004)	0.32
" We evaluated in a murine model of tuberculosis the activity of carbapenems alone and combined with clavulanate against Mycobacterium tuberculosis."	( Activity of carbapenems combined with clavulanate against murine tuberculosis. Jarlier, V; Mainardi, JL; Truffot, C; Veziris, N, 2011)	0.37
"2%) of the 121 MDR-TB strains were subjected to a synergistic effect when the drug was combined with sulbactam, tazobactam, or clavulanate, respectively."	( In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates. Lu, J; Pang, Y; Wang, Y; Zhang, D, 2016)	0.43

Excerpt	Reference	Relevance
"The pharmacokinetics and bioavailability of ticarcillin and clavulanate were determined after intravenous (i."	( Pharmacokinetics and bioavailability of ticarcillin and clavulanate in foals after intravenous and intramuscular administration. Baggot, JD; Hietala, SK; Pryor, P; Spensley, MS; Wilson, WD, 1991)	0.28
"9 hours, with bioavailability of 54."	( Pharmacokinetics of intravenously and intramuscularly administered ticarcillin and clavulanic acid in foals. Beech, J; Simmons, RD; Sweeney, RW, 1988)	0.27
" The bioavailability of ticarcillin was 84."	( Pharmacokinetics of ticarcillin and clavulanic acid given in combination to adult horses by intravenous and intramuscular routes. Beech, J; Simmons, RD; Soma, LR; Sweeney, RW, 1988)	0.27
" In spite of initial faster absorption, the intramuscular bioavailability of CLA (65."	( Serum levels and pharmacokinetics of ticarcillin and clavulanic acid in dog following parenteral administration of Timentin. Garg, RC; Keefe, TJ; Vig, MM, 1987)	0.27
" The mean absolute bioavailability was 64%."	( The disposition of clavulanic acid in man. Allen, GD; Bolton, GC; Davies, BE; Filer, CW; Jeffery, DJ, 1986)	0.27
" 1980] have shown that the bioavailability of Augmentin is not affected by food."	( Augmentin bioavailability following cimetidine, aluminum hydroxide and milk. Clarke, HL; Horton, R; Jackson, D; Lau, D; Staniforth, DH, 1985)	0.27
" Concentrations of the drugs in blood, tissue fluid and skin showed that both drugs were sufficiently well absorbed and distributed to allow a prediction of efficacy against infections caused by beta-lactamase producing bacteria."	( Clavulanate-potentiated amoxycillin: activity in vitro and bioavailability in the dog. Buswell, JF; Bywater, RJ; Palmer, GH; Stanton, A, 1985)	0.27
"The bioavailability and pharmacokinetics of clavulanic acid were studied following oral solution and rapid intravenous administration to healthy volunteers."	( Bioavailability and pharmacokinetics of clavulanic acid in healthy subjects. Clarke, JG; Coates, PE; Davies, BE; Sutton, JA; Thawley, AR, 1985)	0.27
" The bioavailability of the oral dose averaged 60."	( Pharmacokinetics of clavulanic acid, given in combination with amoxycillin, in volunteers. Fellner, H; Hedström, SA; Nilsson-Ehle, I; Nilsson-Ehle, P; Sjövall, J, 1985)	0.27
" Clavulanic acid is well absorbed when given by mouth and a formulation with amoxycillin (Augmentin; Beechams) is now available for clinical use."	( The history and background of Augmentin. Rolinson, GN, 1982)	0.26
" Bioavailability was 27% for amoxicillin and 50% for clavulanic acid."	( Pharmacokinetics of amoxicillin/clavulanic acid combination after intravenous and oral administration in goats. Carceles, CM; Carli, S; Escudero, E; Serrano, JM; Vicente, MS, 1995)	0.29
" The bioavailability after the intramuscular injection was high and similar for both drugs (75."	( Pharmacokinetics of amoxicillin/clavulanic acid combination after intravenous and intramuscular administration to pigeons. Carceles, CM; Escudero, E; Vicente, MS, )	0.13
" Excellent tissue pharmacokinetics and oral bioavailability suggest usefulness in the treatment of complicated intra-abdominal infections."	( Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group. Bur, F; Donahue, PE; Luke, DR; Mintz, SJ; Smith, DL; Yellin, AE, 1998)	0.3
" administration both drugs were poorly absorbed into the plasma."	( Administration of ticarcillin in combination with clavulanic acid intravenously and intrauterinely to clinically normal oestrous mares. Papich, MG; Van Camp, SD; Whitacre, MD, 2000)	0.31
" The ozone absorption rate ranged between 53% (ozonation) and 68% (perozonation)."	( Combined chemical and biological oxidation of penicillin formulation effluent. Alaton, IA; Baykal, E; Dogruel, S; Gerone, G, 2004)	0.32
" Data available in the literature also suggest a possible interaction between amoxicillin and clavulanic acid that might decrease the absolute bioavailability of clavulanic acid."	( New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review. Sánchez Navarro, A, 2005)	0.33
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
" bioavailability was found to be 22."	( Disposition and oral bioavailability of amoxicillin and clavulanic acid in pigs. Baert, K; Croubels, S; De Backer, P; De Boever, S; Gasthuys, F; Reyns, T; Schauvliege, S, 2007)	0.34
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" Oral bioavailability of amoxicillin was 79."	( Population pharmacokinetics and dosing simulations of amoxicillin in obese adults receiving co-amoxiclav. Burdet, C; Carette, C; Crémieux, AC; Czernichow, S; Duval, X; El-Helali, N; Hammas, K; Massias, L; Mellon, G; Mentré, F, 2020)	0.56

Excerpt	Relevance	Reference
" The emergence of the newer antibiotic classes, including the second and third-generation cephalosporins and the fluoroquinolones, has provided the clinician with agents that offer a broad spectrum of activity, good patient acceptance, a well-tolerated safety profile, and convenient dosage regimens due to their unique pharmacokinetic profiles."	( New considerations in treatment of urinary tract infections in adults. Faro, S, 1992)	0.28
" Ticarcillin and clavulanic acid is a safe and effective alternative to gentamicin and clindamycin in the treatment of secondary bacterial peritonitis and offers advantages in dosing simplicity and freedom from ototoxic and nephrotoxic effects."	( A randomized trial of ticarcillin and clavulanate versus gentamicin and clindamycin in patients with complicated appendicitis. Levine, BA; Sirinek, KR, 1991)	0.28
"Concentrations of amoxycillin/clavulanic acid achievable in the respiratory tract following oral dosage were assessed for in-vitro activity against beta-lactamase-producing strains of Branhamella catarrhalis and Haemophilus influenzae."	( Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against beta-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae. Cooper, CE; Slocombe, B; White, AR, 1990)	0.28
" While it is eliminated mainly by the kidney, 10-20% of the drug is eliminated in the bile and ceftriaxone salt precipitates have been described in the gallbladder of animals dosed with ceftriaxone."	( Incidence of gallbladder lithiasis after ceftriaxone treatment. Anderegg, A; Cantoni, L; Cometta, A; Gallot-Lavallée-Villars, S; Glauser, MP; Gonvers, JJ; Iten, A, 1990)	0.28
" Of the 24 children with urinary tract infection for the first time, combination therapy, dosing twice daily for 5 days (40 mg/kg."	( Amoxycillin and clavulanic acid in the treatment of urinary tract infections in children. D'Eufemia, P; Giardini, O; Martino, F; Ruberto, U, )	0.13
"5 mg/5 ml (4:1 ratio) at the dosage of about 17 mg/kg in two daily administrations according to the weight of the patients was used."	( [Pediatric suspensions of amoxicillin and clavulanic acid in the treatment of bacterial infections of otorhinolaryngologic importance and the upper respiratory tract]. Amendola, F; De Mattia, D; Natuzzi, M; Schettini, F, 1989)	0.28
" The dosage of amoxycillin was 50 mg/kg/day given together with probenecid and divided in 3 doses."	( Comparison of amoxycillin/clavulanate with amoxycillin in children and adults with chronic obstructive pulmonary disease and infection with Haemophilus influenzae. Bondesson, G; Høiby, N; Jensen, T; Koch, C; Pedersen, SS; Stafanger, G, 1988)	0.27
" The dosing requirements for the combination of TIC and CLAV in patients with renal failure are considered."	( Pharmacokinetics of clavulanic acid-potentiated ticarcillin in renal failure. Boulton-Jones, M; Henderson, I; Payton, CD; Stewart, MJ; Watson, ID, 1987)	0.27
" Dosage recommendations are suggested which prevent undue accumulations of amoxicillin while maintaining adequate concentrations of clavulanic acid."	( Differential effect of impaired renal function on the kinetics of clavulanic acid and amoxicillin. Descoeudres, C; Frey, FJ; Horber, FF; Murray, AT; Reubi, FC, 1986)	0.27
" Clavulanic acid was the major radioactive component present in 0-24 h urine following oral dosing (23% of the dose)."	( The disposition of clavulanic acid in man. Allen, GD; Bolton, GC; Davies, BE; Filer, CW; Jeffery, DJ, 1986)	0.27
" For general condition, dogs dosed with CVA-K at 100 mg/kg showed reddening of the skin and mucous membranes, shaking of the head, facial oedema, a decrease in food intake and a reduction in body weight."	( [Chronic intravenous toxicity studies of potassium clavulanate and BRL28500 in dogs]. Katayama, T; Kobayashi, K; Koshima, Y; Koyanagi, J; Koyu, A; Kurakata, Y; Nagata, R; Nishioka, Y; Onishi, M; Sato, M, 1986)	0.27
" A formulation containing amoxycillin trihydrate and potassium clavulanate (4:1) was dosed to beagles at 12."	( Clavulanate-potentiated amoxycillin: activity in vitro and bioavailability in the dog. Buswell, JF; Bywater, RJ; Palmer, GH; Stanton, A, 1985)	0.27
" The bactericidal effects of the antibiotic combination were measured in an in vitro kinetic model in which the drug concentrations were varied to simulate those measured in humans after intravenous dosing with ticarcillin (3."	( Antibacterial activity of ticarcillin in the presence of clavulanate potassium. Beale, AS; Boon, RJ; Griffin, KE; Slocombe, B; Stokes, DH; Sutherland, R; White, AR, 1985)	0.27
" Due to accumulation, dosage adjustment is required for patients with renal insufficiency."	( Pharmacology of ticarcillin combined with clavulanic acid in humans. Chin, NX; Neu, HC; Scully, BE, 1985)	0.27
" A higher bacterial kill rate was observed when the antibiotic dosage was increased beyond the minimum concentration where an antibacterial effect was seen; this was not demonstrable by traditional agar dilution tests."	( Antibacterial activity and kill kinetics of amoxicillin-clavulanic acid combinations against Escherichia coli and Klebsiella aerogenes. Bergan, T; Fuglesang, JE, )	0.13
" These data indicate that dosage adjustments for amoxicillin/clavulanic acid may be required in patients with chronic renal failure who are on hemodialysis."	( Effects of hemodialysis on the pharmacokinetics of amoxicillin/clavulanic acid combination. Brass, C; Kohli, R; Slaughter, RL, 1984)	0.27
" Mean plasma concentrations 5 min after dosing were 89."	( Single-dose pharmacokinetics of intravenous clavulanic acid with amoxicillin in pediatric patients. Casey, PA; Cooper, DL; Schaad, UB, 1983)	0.27
" The smaller dosage resulted in suboptimal plasma concentrations."	( Pharmacokinetics of potassium clavulanate in combination with amoxicillin in pediatric patients. Kusmiesz, H; Nelson, JD; Shelton, S, 1982)	0.26
" Even though the differences in disposition kinetics of both drugs were statistically significant, the same intravenous dosing rate of this antimicrobial combination can generally be used in sheep and goats."	( Comparative pharmacokinetics of amoxicillin/clavulanic acid combination after intravenous administration to sheep and goats. Baggot, JD; Carceles, CM; Escudero, E, 1995)	0.29
" Our results suggest that the current dosing recommendations of 75 mg/kg every 12 h risk subtherapeutic clavulanic acid concentrations and that 50 mg/kg every 6 h is a more rational dosing strategy."	( Ticarcillin-clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis. Burstein, AH; Carlos, RQ; Diaz, PR; Forrest, A; Gal, P; Ransom, JL; Wyble, LE, 1994)	0.29
" Serum bactericidal titers were determined and used to calculate the duration of measurable bactericidal activity over the dosing interval of each of the regimens against two clinical isolates of Bacillus fragilis, Escherichia coli, Enterococcus faecalis, and Pseudomonas aeruginosa."	( Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa. Klepser, ME; Marangos, MN; Nicolau, DP; Nightingale, CH; Quintiliani, R; Zhu, Z, 1997)	0.3
" These data may have implications for reducing the dosage of amoxicillin-clavulanate."	( Postantibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate. Molesworth, SJ; Rittenhouse, S; Sutherland, R; Thorburn, CE, 1996)	0.29
" From a single administration it is proposed that an intramuscular dosage regimen of 105 mg kg(-1) of the combination (84 mg kg(-1) of amoxicillin and 21 mg kg(-1) of clavulanic acid) every 12 hours will achieve minimum concentrations > or =0."	( Pharmacokinetics of amoxicillin/clavulanic acid combination after intravenous and intramuscular administration to pigeons. Carceles, CM; Escudero, E; Vicente, MS, )	0.13
"In vivo, serum concentrations of beta-lactamase inhibitors measured during the last part of the dosing interval are below the levels associated with in vitro activity."	( [In vitro demonstration of a true post-beta-lactamases inhibitor effect (PLIE) of clavulanic acid on Klebsiella pneumoniae and Haemophilus influenzae]. Dhoyen, N; Jehl, F; Linger, L; Monteil, H; Murbach, V, 1999)	0.3
" The dosage was 500 mg once or twice a day depending on the studies."	( [Levofloxacin in the treatment of community-acquired pneumococcal pneumonia]. Léophonte, P; Veyssier, P, 1999)	0.3
" Cost saving may be achieved with trovafloxacin due to the lack of any need to monitor creatinine levels and the once-daily dosing regimen that allows a switch to the same orally administered drug."	( Treatment of complicated intra-abdominal infections: comparison of the tolerability and safety of intravenous/oral trovafloxacin versus intravenous imipenem/cilastatin switching to oral amoxycillin/clavulanic acid. Luke, DR; Peterson, J, )	0.13
" Despite the marked effect of certain antibiotic agents upon spermatogenesis, it appears that clavulanic acid-potentiated amoxycillin can be used in dogs at up to twice the therapeutic dosage recommended by the manufacturer without a deleterious effect upon semen quality."	( Effect of clavulanic acid-potentiated amoxycillin on semen quality in dogs. England, GC, 1999)	0.3
" Thirteen adverse events were reported post dosing by 7 subjects."	( Bioequivalence study of a novel Solutab tablet formulation of amoxicillin/clavulanic acid versus the originator film-coated tablet. Bertola, MA; Rayer, B; Sourgens, H; Steinbrede, H; Verschoor, JS, 2001)	0.31
"A simple and sensitive liquid chromatographic method with electrochemical (EC) detection is described for the quantitative determination of amoxycillin and clavulanic acid in pharmaceutical dosage forms."	( Simultaneous determination of amoxycillin and clavulanic acid in pharmaceutical dosage forms by LC with amperometric detection. Aghazadeh, A; Kazemifard, G, 2001)	0.31
" The new formulation consisted of 1 layer of immediate-release amoxicillin and clavulanate and another of sustained-release amoxicillin in a proportion such that for an amoxicillin minimum inhibitory concentration (MIC) of 4 microg/mL, the time above the MIC (T >MIC) would be approximately > or = 40% over a 12-hour dosing interval."	( The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Allen, A; Bird, N; Davy, M; Dewit, O; Kaye, CM; McDonagh, M; Perry, S; Storm, K, 2001)	0.31
"4% of a 12-hour dosing interval, a value that cannot be achieved with existing approved doses and formulations of amoxicillin/clavulanate."	( The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Allen, A; Bird, N; Davy, M; Dewit, O; Kaye, CM; McDonagh, M; Perry, S; Storm, K, 2001)	0.31
"The PLIE could be one of several factors explaining why beta-lactam/beta-lactamase inhibitor combinations remain effective throughout the dosing interval, even if a few hours after in vivo administration, serum concentrations of beta-lactamase inhibitor fall below levels that are active in vitro."	( Evidence for a true post-beta-lactamase-inhibitor effect of clavulanic acid against Klebsiella pneumoniae and Haemophilus influenzae. Dhoyen, N; Jehl, F; Linger, L; Monteil, H; Murbach, V, 2001)	0.31
" Today, the beta-lactam antibiotics, particularly penicillins and cephalosporins, represent the world's major biotechnology products with worldwide dosage form sales of approximately 15 billion US dollars or approximately 65% of the total world market for antibiotics."	( Industrial production of beta-lactam antibiotics. Elander, RP, 2003)	0.32
" The dosing regimens were as follows: piperacillin alone, 4 g piperacillin/0."	( Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase. Li, C; Lister, PD; Nicolau, DP; Nightingale, CH; Quintiliani, R, 2004)	0.32
" Eradication was achieved with the enhanced formulation for strains with a MIC of < or =2 mg/L, however, regrowth occurred with the other dosing regimens."	( Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens. Cars, O; Löwdin, E; Odenholt, I, 2004)	0.32
" This study also investigated whether urinary concentrations obtained after dosing cover E coli strains categorized as intermediately resistant and resistant based on current Clinical and Laboratory Standards Institute (formerly NCCLS) breakpoints in uncomplicated cystitis."	( Urinary concentrations and bactericidal activity against amoxicillin-nonsusceptible strains of Escherichia coli with single-dose, oral, sustained-release amoxicillin/clavulanic acid: a phase I, open-label, noncomparative clinical trial in healthy voluntee Aguilar, L; Carcas, A; Carpintero, Y; del Prado, G; Giménez, MJ; Gracia, M; Huelves, L; Maín, CM; Ponte, C; Soriano, F, 2005)	0.33
"In this Phase I study in healthy volunteers, urinary concentrations after dosing with amoxicillin/clavulanic acid 2000/125 mg SR showed bactericidal activity against the amoxicillin-susceptible and intermediately resistant strains of E coli."	( Urinary concentrations and bactericidal activity against amoxicillin-nonsusceptible strains of Escherichia coli with single-dose, oral, sustained-release amoxicillin/clavulanic acid: a phase I, open-label, noncomparative clinical trial in healthy voluntee Aguilar, L; Carcas, A; Carpintero, Y; del Prado, G; Giménez, MJ; Gracia, M; Huelves, L; Maín, CM; Ponte, C; Soriano, F, 2005)	0.33
"We conducted a prospective pharmacokinetic study of oral co-amoxiclav in patients with melioidosis to determine the optimal dosage and dosing interval in this potentially fatal infection."	( Pharmacokinetic and pharmacodynamic assessment of co-amoxiclav in the treatment of melioidosis. Chaowagul, W; Chierakul, W; Dance, DA; Day, NP; Lindegardh, N; Maharjan, B; Peacock, SJ; Pongtavornpinyo, W; Short, JM; Singtoroj, T; Teparrukkul, P; Wangboonskul, J; White, NJ; Wuthiekanun, V, 2006)	0.33
" The experimental bactericidal activity of cefditoren is maintained over the dosing interval regardless of the presence of a mutation in the ftsI gene or beta-lactamase production."	( influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi Aguilar, L; Alou, L; Cafini, F; Coronel, P; Echeverría, O; Giménez, MJ; González, N; Prieto, J; Sevillano, D; Torrico, M, 2007)	0.34
") dosage of 20 mg/kg of amoxicillin and 5 mg/kg of clavulanic acid."	( Disposition and oral bioavailability of amoxicillin and clavulanic acid in pigs. Baert, K; Croubels, S; De Backer, P; De Boever, S; Gasthuys, F; Reyns, T; Schauvliege, S, 2007)	0.34
" We used NONMEM and S-ADAPT for population pharmacokinetic analysis and a target time of the non-protein-bound drug concentration above the MIC for > or = 50% of the dosing interval for near-maximal bactericidal activity in serum."	( Bone penetration of amoxicillin and clavulanic acid evaluated by population pharmacokinetics and Monte Carlo simulation. Bulitta, JB; Gusinde, J; Hennig, FF; Holzgrabe, U; Kinzig, M; Landersdorfer, CB; Sörgel, F, 2009)	0.35
" The CLA dosage (13 mg/kg of body weight given intraperitoneally) was chosen to reach a maximum concentration of the drug in serum similar to that in humans and a time during which the serum CLA concentration remained above the MIC equivalent to 40% of the interval between doses."	( In vitro activity and in vivo efficacy of clavulanic acid against Acinetobacter baumannii. Beceiro, A; Bou, G; Docobo-Pérez, F; Domínguez-Herrera, J; López-Rojas, R; Pachón, J, 2009)	0.35
"Two accurate, precise, sensitive and economical procedures for simultaneous estimation of Cefpodoxime proxetil and Potassium clavulanate in tablet dosage form have been developed."	( Simultaneous spectrophotometric determination of Cefpodoxime proxetil and Potassium clavulanate. Gandhi, SV; Patil, NG; Patil, UP, 2009)	0.35
" The aim of the study was to assess the pharmacokinetic properties of amoxicillin and clavulanic acid in 8:1 with different dosage in healthy volunteers and provide support for this drug to obtain marketing authorization in China."	( Pharmacokinetics study of amoxycillin and clavulanic acid (8:1)--a new combination in healthy Chinese adult male volunteers using the LC-MS/MS method. Jia, Z; Men, X; Wang, R; Wang, Y; Xie, H; Xu, L; Zhang, J; Zhang, Q, 2013)	0.39
" Based on pharmacokinetic/pharmacodynamic indexes reported for beta-lactams against other bacterial pathogens, a cumulative percentage of a 24-h period that the drug concentration exceeds the MIC under steady-state pharmacokinetic conditions (%TMIC) of 20 to 40% was achieved in mice using a suitable dosing regimen."	( In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis. Ahuja, V; Balasubramanian, V; Balganesh, M; Bhattacharjee, D; Dinesh, N; Ganguly, S; Kumar, N; Panduga, V; Parab, M; Ramachandran, V; Reddy, J; Shandil, R; Sharma, S; Solapure, S; Vishwas, KG, 2013)	0.39
" The dosage of amoxicillin was considered to be appropriate when in accord with clinical practice guidelines, that is, 80-90 mg/kg/day."	( High-dose amoxicillin with clavulanate for the treatment of acute otitis media in children. Chu, CH; Ho, CY; Huang, CY; Liao, WH; Lin, LY; Shiao, AS; Tu, TY; Wang, MC, 2013)	0.39
"The majority of prescriptions were under dosage (89."	( High-dose amoxicillin with clavulanate for the treatment of acute otitis media in children. Chu, CH; Ho, CY; Huang, CY; Liao, WH; Lin, LY; Shiao, AS; Tu, TY; Wang, MC, 2013)	0.39
"Amoxicillin-clavulanate (A/C) is currently the most effective oral antimicrobial in treating children with acute otitis media (AOM), but the standard dosage of 90 mg amoxicillin/6."	( Reduced-Concentration Clavulanate for Young Children with Acute Otitis Media. Beumer, J; Bhatnagar, S; Haralam, M; Hoberman, A; Jeong, JH; Kearney, DH; Kurs-Lasky, M; Martin, JM; Miah, MK; Muñiz, G; Nagg, JP; Paradise, JL; Pope, MA; Rockette, HE; Shaikh, N; Shope, TR; Venkataramanan, R; Zhao, W, 2017)	0.46
"Chronic dosing of clavulanic acid alleviates neuropathic pain in rats and up-regulates glutamate transporters both in vitro and in vivo."	( The β-lactam clavulanic acid mediates glutamate transport-sensitive pain relief in a rat model of neuropathic pain. Bjerrum, OJ; Gegelashvili, G; Heegaard, AM; Kristensen, PJ; Munro, G, 2018)	0.48
" Solid dosage forms containing amoxicillin alone or in combination with clavulanic acid as well as analgesics containing paracetamol alone or in combination with other drugs were sampled in a randomized fashion from the formal market (pharmacies) and by convenient sampling from the informal market."	( Drug Quality in South Africa: A Field Test. Dressman, J; Katerere, DR; Lehmann, A, 2018)	0.48
" Since the achievement and maintenance of optimum therapeutic levels of β-lactam antibiotics is critical for the resolution of many infectious clinical situations, and to avoid antibiotic resistance generation, the design of new non-aqueous dosage forms is urgent."	( A Natural Deep Eutectic Solvent Formulated to Stabilize β-Lactam Antibiotics. Calderón, C; M Munita, J; Martínez, F; Olivares, B; R Campodonico, P; Rivas, L, 2018)	0.48
" No dose-response relationship was found between exposure in terms of the defined daily dose and major malformations."	( The safety of amoxicillin and clavulanic acid use during the first trimester of pregnancy. Daniel, S; Doron, M; Fishman, B; Koren, G; Levy, A; Lunenfeld, E, 2019)	0.51
" Dosing in this case was complicated by the necessity for RRT to treat a drug overdose with carbamazepine, despite normal native renal function."	( Amoxicillin-Clavulanate Dosing in the Intensive Care Unit: The Additive Effect of Renal Replacement Therapy in a Patient with Normal Kidney Function. Lipman, J; Livermore, A; Lonsdale, DO; McWhinney, B; Roberts, JA; Ungerer, JPJ, 2019)	0.51
" Findings from this study aid in ameliorating current dosing regimens to optimise antibiotic efficacy."	( Suitability of Amoxicillin-Clavulanic Acid for Administration via Prolonged Infusion. Barton, S; Dixon, B; Fawaz, S; Mohamed, A; Nabhani-Gebara, S, 2020)	0.56
"Pneumonia, skin and soft tissue infections are more frequent in obese patients and are most often treated by co-amoxiclav, using similar dosing regimens to those used for non-obese subjects."	( Population pharmacokinetics and dosing simulations of amoxicillin in obese adults receiving co-amoxiclav. Burdet, C; Carette, C; Crémieux, AC; Czernichow, S; Duval, X; El-Helali, N; Hammas, K; Massias, L; Mellon, G; Mentré, F, 2020)	0.56
" Its inclusion in the treatment of infectious diseases of broilers requires determination of pharmacokinetic and pharmacodynamic parameters in order to determine the appropriate dosage for broilers and ensure safety of chicken products for human health."	( Mass spectrometric identification and quantification of the antibiotic clavulanic acid in broiler chicken plasma and meat as a necessary analytical tool in finding ways to increase the effectiveness of currently used antibiotics in the treatment of broile Bartejsova, I; Matiaskova, K; Nedbalcova, K; Putecova, K; Stastny, K; Zouharova, M, 2021)	0.62
" The dosing of clavulanic acid is currently based on that of the partner drug (amoxicillin or ticarcillin)."	( Pharmacokinetics of Clavulanic Acid in the Pediatric Population: A Systematic Literature Review. Allegaert, K; Keij, FM; Koch, BCP; Kornelisse, RF; Muller, AE; Reiss, IKM; Tramper-Stranders, GA, 2022)	0.72
" Neonates (postmenstrual age ≥35 weeks, postnatal age 0-28 days, bodyweight ≥2 kg) in whom prolonged antibiotic treatment was indicated because of a probable bacterial infection, were randomly assigned (1:1) to switch to an oral suspension of amoxicillin 75 mg/kg plus clavulanic acid 18·75 mg/kg (in a 4:1 dosing ratio, given daily in three doses) or continue on intravenous antibiotics (according to the local protocol)."	( Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiorit Allegaert, K; Baartmans, MGA; den Butter, PCP; Driessen, GJA; Eijkemans, M; Hartwig, NG; Heidema, J; Keij, FM; Kenter, S; Kornelisse, RF; Meijssen, CB; Norbruis, OF; Qi, H; Reiss, IKM; Stam-Stigter, GM; Tramper-Stranders, GA; van Beek, RHT; van Dalen-Vink, I; van den Berg, MM; van der Meer-Kappelle, LH; van der Sluijs-Bens, J; van Driel, A; van Rooij, LGM; van Rossem, MC; von Lindern, JS, 2022)	0.72
"Selection of an antibiotic and dosing regimen requires consideration of multiple factors including microbiological data, site of infection, pharmacokinetics, and how it relates to the pharmacodynamic target."	( Shedding Light on Amoxicillin, Amoxicillin-clavulanate, and Cephalexin Dosing in Children from a Pharmacist's Perspective. Bio, LL; Yu, D, 2022)	0.72
" The starting dosage was 2875 g of amoxicillin twice daily and 125 mg of clavulanic acid twice daily."	( Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections Due to Extended-Spectrum Beta-Lactamase (ESBL)-Producing Klebsiella pneumoniae. Ciszek, M; Hryniewiecka, E; Jasińska, K; Pączek, L; Wilkowski, P, 2023)	0.91

Role	Description
EC 3.5.2.6 (beta-lactamase) inhibitor	An EC 3.5.2.* (non-peptide cyclic amide C-N hydrolase) inhibitor that interferes with the action of beta-lactamase (EC 3.5.2.6).
antibacterial drug	A drug used to treat or prevent bacterial infections.
bacterial metabolite	Any prokaryotic metabolite produced during a metabolic reaction in bacteria.
anxiolytic drug	Anxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
oxapenam	A fused-ring beta-lactam system where the beta-lactam ring is fused to a 1,3-oxazolidine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-lactamase	Klebsiella pneumoniae	IC50 (µMol)	1.7200	0.0800	0.9000	1.7200	AID519751
Beta-lactamase	Escherichia coli	IC50 (µMol)	0.0700	0.0100	2.0933	6.2000	AID326273
Beta-lactamase	Citrobacter gillenii	IC50 (µMol)	0.0090	0.0090	0.0245	0.0400	AID285444
Beta-lactamase	Escherichia coli	IC50 (µMol)	500.0000	0.0260	0.0290	0.0320	AID394491
Beta-lactamase	Shouchella clausii	IC50 (µMol)	0.0850	0.0040	0.0547	0.0850	AID373218
Beta-lactamase	Pseudomonas aeruginosa	IC50 (µMol)	0.1000	0.0600	0.1700	0.3700	AID511293
Beta-lactamase	Pseudomonas aeruginosa	IC50 (µMol)	0.1000	0.1000	1.7000	3.0000	AID495659
Bile salt export pump	Rattus norvegicus (Norway rat)	IC50 (µMol)	1,000.0000	0.4000	2.7500	8.6000	AID1209456
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	1,000.0000	0.1100	7.1903	10.0000	AID1209455
Beta-lactamase	Staphylococcus aureus	IC50 (µMol)	0.0800	0.0800	1.9509	6.5000	AID43913
Beta-lactamase	Escherichia coli K-12	IC50 (µMol)	500.0075	0.0150	2.4657	8.0000	AID154308; AID43568
Beta-lactamase	Enterobacter cloacae	IC50 (µMol)	118.1000	0.1000	1.8745	7.7000	AID297200; AID584977
Neutrophil elastase	Homo sapiens (human)	IC50 (µMol)	40.0000	0.0063	2.0734	22.3780	AID66646
Beta-lactamase SHV-1	Escherichia coli	IC50 (µMol)	0.0280	0.0280	0.1250	0.2220	AID297199
Beta-lactamase SHV-1	Klebsiella pneumoniae	IC50 (µMol)	0.1700	0.1100	0.1500	0.1700	AID519750; AID519984
Beta-lactamase SHV-1	Klebsiella pneumoniae	Ki	2.0000	0.2200	1.2400	2.0000	AID1801066
Beta-lactamase OXA-1	Escherichia coli	IC50 (µMol)	3.2000	3.2000	4.0000	4.8000	AID43565
Cytochrome P450 2B6	Homo sapiens (human)	IC50 (µMol)	0.1700	0.0011	3.4186	10.0000	AID519750
Beta-lactamase	Pseudomonas aeruginosa PAO1	IC50 (µMol)	50.4000	0.1280	1.6916	4.6000	AID43885; AID584978
Beta-lactamase TEM	Escherichia coli	IC50 (µMol)	9.2560	0.0019	1.7618	10.0000	AID297198; AID326275; AID372630; AID43566; AID50695
Beta-lactamase TEM	Escherichia coli	Ki	0.8000	0.0270	1.8234	7.3000	AID43582
Beta-lactamase	Mycobacterium tuberculosis CDC1551	Ki	6.3000	6.3000	6.3000	6.3000	AID1801074
Beta-lactamase	Acinetobacter pittii	IC50 (µMol)	235.5200	1.1200	1.1200	1.1200	AID555229
Beta-lactamase	Acinetobacter pittii	IC50 (µMol)	1,462.4800	7.7580	7.7580	7.7580	AID555230
Beta-lactamase	Salmonella enterica subsp. enterica serovar Westhampton	IC50 (µMol)	0.0100	0.0022	0.0061	0.0100	AID556339
Beta-lactamase	Pseudomonas aeruginosa	IC50 (µMol)	0.1000	0.1000	1.7000	3.0000	AID495660
Beta-lactamase	Klebsiella pneumoniae	IC50 (µMol)	0.0200	0.0200	0.0200	0.0200	AID519985
Class D beta-lactamase	Brachyspira pilosicoli	IC50 (µMol)	2.0000	0.1600	1.0800	2.0000	AID519637
Beta-lactamase	Enterobacter cloacae	IC50 (µMol)	100.0000	3.4000	3.4000	3.4000	AID50709
Beta-lactamase	Pseudomonas luteola	IC50 (µMol)	0.0360	0.0360	0.0380	0.0400	AID495653
Beta-lactamase	Escherichia coli	IC50 (µMol)	8.6000	0.2400	4.4200	8.6000	AID372627
Beta-lactamase	Serratia fonticola	IC50 (µMol)	72.8000	6.9000	6.9000	6.9000	AID374027
Beta-lactamase	Escherichia coli	IC50 (µMol)	0.0090	0.0020	0.0055	0.0090	AID368519
Carbapenem-hydrolyzing beta-lactamase KPC	Klebsiella pneumoniae	IC50 (µMol)	10.5000	0.3700	0.3720	0.3740	AID495801
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-lactamase TEM	Escherichia coli	Activity	3.0000	3.0000	3.0000	3.0000	AID326269
Beta-lactamase class B VIM-2	Pseudomonas aeruginosa	Km	5,000.0000	2.0000	6.6500	9.4000	AID531315
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
antibiotic catabolic process	Beta-lactamase	Escherichia coli K-12
response to antibiotic	Beta-lactamase	Escherichia coli K-12
proteolysis	Neutrophil elastase	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Neutrophil elastase	Homo sapiens (human)
response to yeast	Neutrophil elastase	Homo sapiens (human)
leukocyte migration involved in inflammatory response	Neutrophil elastase	Homo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-negative bacteria	Neutrophil elastase	Homo sapiens (human)
proteolysis	Neutrophil elastase	Homo sapiens (human)
intracellular calcium ion homeostasis	Neutrophil elastase	Homo sapiens (human)
response to UV	Neutrophil elastase	Homo sapiens (human)
extracellular matrix disassembly	Neutrophil elastase	Homo sapiens (human)
protein catabolic process	Neutrophil elastase	Homo sapiens (human)
response to lipopolysaccharide	Neutrophil elastase	Homo sapiens (human)
negative regulation of chemokine production	Neutrophil elastase	Homo sapiens (human)
negative regulation of interleukin-8 production	Neutrophil elastase	Homo sapiens (human)
positive regulation of interleukin-8 production	Neutrophil elastase	Homo sapiens (human)
defense response to bacterium	Neutrophil elastase	Homo sapiens (human)
positive regulation of MAP kinase activity	Neutrophil elastase	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Neutrophil elastase	Homo sapiens (human)
negative regulation of inflammatory response	Neutrophil elastase	Homo sapiens (human)
positive regulation of immune response	Neutrophil elastase	Homo sapiens (human)
negative regulation of chemotaxis	Neutrophil elastase	Homo sapiens (human)
pyroptosis	Neutrophil elastase	Homo sapiens (human)
neutrophil-mediated killing of gram-negative bacterium	Neutrophil elastase	Homo sapiens (human)
neutrophil-mediated killing of fungus	Neutrophil elastase	Homo sapiens (human)
positive regulation of leukocyte tethering or rolling	Neutrophil elastase	Homo sapiens (human)
phagocytosis	Neutrophil elastase	Homo sapiens (human)
acute inflammatory response to antigenic stimulus	Neutrophil elastase	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2B6	Homo sapiens (human)
cellular ketone metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2B6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
beta-lactamase activity	Beta-lactamase	Escherichia coli K-12
hydrolase activity	Beta-lactamase	Escherichia coli K-12
protease binding	Neutrophil elastase	Homo sapiens (human)
transcription corepressor activity	Neutrophil elastase	Homo sapiens (human)
endopeptidase activity	Neutrophil elastase	Homo sapiens (human)
serine-type endopeptidase activity	Neutrophil elastase	Homo sapiens (human)
protein binding	Neutrophil elastase	Homo sapiens (human)
heparin binding	Neutrophil elastase	Homo sapiens (human)
peptidase activity	Neutrophil elastase	Homo sapiens (human)
cytokine binding	Neutrophil elastase	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-alpha-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
heme binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-beta-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2B6	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
outer membrane-bounded periplasmic space	Beta-lactamase	Escherichia coli K-12
periplasmic space	Beta-lactamase	Escherichia coli K-12
extracellular region	Neutrophil elastase	Homo sapiens (human)
extracellular space	Neutrophil elastase	Homo sapiens (human)
cytoplasm	Neutrophil elastase	Homo sapiens (human)
cytosol	Neutrophil elastase	Homo sapiens (human)
cell surface	Neutrophil elastase	Homo sapiens (human)
secretory granule	Neutrophil elastase	Homo sapiens (human)
azurophil granule lumen	Neutrophil elastase	Homo sapiens (human)
specific granule lumen	Neutrophil elastase	Homo sapiens (human)
phagocytic vesicle	Neutrophil elastase	Homo sapiens (human)
collagen-containing extracellular matrix	Neutrophil elastase	Homo sapiens (human)
extracellular exosome	Neutrophil elastase	Homo sapiens (human)
transcription repressor complex	Neutrophil elastase	Homo sapiens (human)
extracellular space	Neutrophil elastase	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2B6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2B6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2B6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1801066	Steady-State Kinetics Assay from Article 10.1021/bi501197t: \\Detecting a quasi-stable imine species on the reaction pathway of SHV-1 u00DF-lactamase and 6u00DF-(hydroxymethyl)penicillanic acid sulfone.\\	2015	Biochemistry, Jan-27, Volume: 54, Issue:3	Detecting a quasi-stable imine species on the reaction pathway of SHV-1 β-lactamase and 6β-(hydroxymethyl)penicillanic acid sulfone.
AID1801074	Steady State Kinetics from Article 10.1021/acs.biochem.5b00698: \\Kinetic and Structural Characterization of the Interaction of 6-Methylidene Penem 2 with the u00DF-Lactamase from Mycobacterium tuberculosis.\\	2015	Biochemistry, Sep-15, Volume: 54, Issue:36	Kinetic and Structural Characterization of the Interaction of 6-Methylidene Penem 2 with the β-Lactamase from Mycobacterium tuberculosis.
AID372637	Inhibition of Escherichia coli DH5alpha CL1179 clone beta-lactamase TEM-152 after 10 mins	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID584973	Inhibition of beta-lactamase SHV-4 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID558547	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P305 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID50695	The compound was tested for its inhibitory activity towards Class A TEM-1 beta-lactamase from Escherichia coli at 0.3 umol	2002	Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6	Design, synthesis and bioactivity evaluation of tribactam beta lactamase inhibitors.
AID1559317	Inhibition of bacterial CTX-M-15 using cefotaxime as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID558773	Antibacterial activity against Campylobacter coli by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID563974	Activity of Klebsiella pneumoniae 05-560 beta-lactamase IMP1 by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID727644	Ratio of Kcat to Kinact for Beta-lactamase SHV-1 K234R protein mutant in Escherichia coli DH10B	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID496599	Inhibition of Escherichia coli DH10B beta-lactamase KPC-2 assessed as residual activity at 25 to 200 uM after 72 hrs by diode array spectrophotometry	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID495660	Inhibition of Pseudomonas aeruginosa 51170 beta-lactamase BEL-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID351648	Cmax in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351640	Unbound drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 1.5 hr	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID558551	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P790 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID558320	Antibacterial activity against Campylobacter jejuni by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID43568	Inhibitory activity against Escherichia coli TEM-3 Beta-lactamase	1998	Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21	Structure-based design of beta-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams.
AID351434	Drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 1 hr	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID584975	Inhibition of beta-lactamase CTX-M-15 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID351635	Unbound drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 6 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID558548	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P316 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID558318	Antibacterial activity against Campylobacter jejuni by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID517929	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli assessed as decrease in zone of inhibition at 30 ug by disk diffusion method in presence of clavulanic acid	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID567284	Binding affinity to Acinetobacter baumannii ADC-33 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID351619	Drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 10 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID377032	Antimicrobial activity against Enterobacter cloacae ATCC 13047 after 24 hrs by disk diffusion assay	2005	Journal of natural products, Jan, Volume: 68, Issue:1	Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID351436	Drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 2 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID52215	Inhibitory activity against cephalosporinase from Proteus morganii TH-64 using cephalothin (40 uM) as a substrate; No inhibition	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.
AID297199	Inhibition of Escherichia coli SHV1	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	4-Substituted trinems as broad spectrum beta-lactamase inhibitors: structure-based design, synthesis, and biological activity.
AID558552	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1093 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID727651	Inhibition of Beta-lactamase SHV-1 K234R protein mutant in Escherichia coli DH10B by Henri-Michaelis-Menten steady state equation analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID351646	Unbound drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 10 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID372627	Inhibition of Escherichia coli DH5alpha beta-lactamase TEM-158	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID525577	Inhibition of Beta-lactamase OXA-24/40 expressed in Escherichia coli BL21 (DE3) by nitrocefin hydrolysis assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Penicillin sulfone inhibitors of class D beta-lactamases.
AID324363	Inhibition of Acinetobacter johnsonii SCO1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
AID543432	Inhibition of Shigella sonnei UIH-1 beta-lactamase CTX-M-64 by spectrophotometry in presence of 100 uM nitrocefin	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID43739	Beta-lactamase inhibitory activity from Klebsiella pneumoniae A20634(TEM) and minimum protective concentration was reported	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID351638	Unbound drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 12 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID556339	Inhibition of Salmonella enterica serotype Westhampton beta-lactamase CTX-M-53	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID1559320	Inhibition of bacterial NDM-1 using cefepime as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID727645	Ratio of Kcat to Kinact for wild type Beta-lactamase SHV-1 in Escherichia coli DH10B	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID558542	Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P835 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID351214	Cmax in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID558561	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter coli isolate P321 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID351651	fAUC (0 to 24 hrs) in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID285275	Inhibition of Escherichia coli BL21(DE3) beta-lactamase TEM29	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID572897	Inhibition of Klebsiella pneumoniae Beta-lactamase SHV-1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor.
AID43117	Minimum protective concentration used to protect the compound against Bacteroides fragilis A-22,695 beta-lactamase catalyzed hydrolysis	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.
AID548270	Ratio of Ki for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237A mutant to Ki for Klebsiella pneumoniae beta-lactamase KPC-2 T237S mutant by competitive assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID351637	Unbound drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 10 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID517930	Antibacterial activity against beta-lactamase-positive ESBL-positive sKlebsiella pneumoniae assessed as decrease in zone of inhibition at 30 ug by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID154308	Inhibition of hydrolysis of nitrocefin after 5 min pre-incubation with P99 beta-lactamases (class C)	2004	Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10	Design and synthesis of bridged gamma-lactams as analogues of beta-lactam antibiotics.
AID351221	Half life of free unbound fraction in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351645	Unbound drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 8 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID519637	Inhibition of Brachyspira pilosicoli beta-lactamase OXA-63 expressed in Escherichia coli BL21 (DE3) assessed as reduction in nitrocefin hydrolysis by spectrophotometry relative to oxacillin	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
AID584987	Inhibition of beta-lactamase TEM-1 after 5 seconds incubation with nitrocefin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID372628	Inhibition of Escherichia coli DH5alpha beta-lactamase TEM-12	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID374027	Inhibition of Serratia fonticola UTAD54 SFC1 beta lactamase expressed in Escherichia coli BL21(DE3) by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID351222	Half life in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID44046	Beta-lactamase inhibitory activity from Staphylococcus aureus A9606 and minimum protective concentration was reported	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID585189	Inhibition of Beta-lactamase GES-2 E104, N170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID70245	Compound was evaluated for minimum inhibitory concentration in the presence of amoxicillin against Escherichia coli A20111	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.
AID1209456	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID351440	Drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 8 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID678718	Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID531314	Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID525576	Inhibition of Beta-lactamase OXA-17 expressed in Escherichia coli BL21 (DE3) by nitrocefin hydrolysis assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Penicillin sulfone inhibitors of class D beta-lactamases.
AID69961	Compound alone was evaluated for minimum inhibitory concentration against Escherichia coli A20111	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.
AID422882	Antimicrobial activity against Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis by broth microdilution assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.
AID558558	Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1699 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID43582	Inhibition constant (Ki) for TEM-1 beta-lactamase	1988	Journal of medicinal chemistry, Feb, Volume: 31, Issue:2	N-aryl 3-halogenated azetidin-2-ones and benzocarbacephems, inhibitors of beta-lactamases.
AID525580	Inhibition of Beta-lactamase OXA-1 expressed in Escherichia coli BL21 (DE3) by nitrocefin hydrolysis assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Penicillin sulfone inhibitors of class D beta-lactamases.
AID496594	Ratio of Kcat to Km for Escherichia coli DH10B beta-lactamase KPC-2	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID351438	Drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 4 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID422500	Inhibition of Carnobacterium divergens BM4489 penicillinase Cad-1	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID558549	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P338 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID531317	Activity of Escherichia coli beta-lactamase VIM-1 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID558540	Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate NCTC 11168 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID558557	Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1698 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID374364	Antimicrobial activity against Aeromonas caviae A324R expressing metallo-beta-lactamase IMP-19 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID541855	Antimicrobial activity against Escherichia coli ATCC 29522 by microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.
AID351632	Unbound drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 2 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID1225760	Inhibition of Escherichia coli recombinant CTX-M-15 assessed as substrate nitrocefin degradation preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometric analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID727641	Binding affinity to wild type Beta-lactamase SHV-1 in Escherichia coli DH10B assessed as change in secondary structure at 50 uM by circular dichroism analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID1559319	Inhibition of bacterial OXA-1 using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID585188	Inhibition of Beta-lactamase GES-7 K104, G170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID285272	Inhibition of Escherichia coli BL21(DE3) beta-lactamase TEM151	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID285273	Inhibition of Escherichia coli BL21(DE3) beta-lactamase TEM152	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID351641	Unbound drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 2 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351656	Protein binding in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID558543	Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P850 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID285444	Inhibition of Citrobacter gillenii CIP 106783 Beta-lactamase GIL1 expressed in Escherichia coli DH10B	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID44049	Minimum protective concentration used to protect the compound against Staphylococcus aureus A9606 beta-lactamase catalyzed hydrolysis	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.
AID372633	Ratio of IC50 for Escherichia coli CF0042 beta-lactamase TEM-35 to IC50 for Escherichia coli DH5alpha beta-lactamase TEM-158	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID326273	Inhibition of Escherichia coli beta-lactamase SCO1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID351636	Unbound drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 8 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID584974	Inhibition of beta-lactamase KPC-2 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID351623	Drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 2 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID368519	Inhibition of Escherichia coli CTX-M-15	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID558545	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P285 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID422883	Antimicrobial activity against 8 ug/ml colistin-subcultured Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis and bacteremia by broth microdilution assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID584991	Activity of beta-lactamase TEM-1 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID297198	Inhibition of Escherichia coli TEM1	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	4-Substituted trinems as broad spectrum beta-lactamase inhibitors: structure-based design, synthesis, and biological activity.
AID44047	Minimum protective concentration against beta-lactamase in Staphylococcus aureus (95 strain)	1997	Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21	Cephalosporin 3'-phloroglucide esters and 7-(phloroglucidamido) cephalosporins as novel antibacterial agents.
AID519751	Inhibition of Klebsiella pneumoniae Beta-Lactamase SHV-72	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID43565	Inhibitory activity against Beta-lactamase type OXA1 (penicillinase) from Escherichia coli OXA1 using ampicillin (40 uM) as a substrate	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.
AID511293	Inhibition of Pseudomonas aeruginosa GES-13 beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID517928	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli assessed as decrease in zone of inhibition at 30 ug by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID373218	Inhibition of Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3)	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID558319	Antibacterial activity against Campylobacter coli by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID50536	In vitro inhibition of Citrobacter freundii 1982 growth.	1998	Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21	Structure-based design of beta-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams.
AID351435	Drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 1.5 hr	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID351624	Drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 3 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351642	Unbound drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 3 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID374361	Antimicrobial activity against Escherichia coli DH5alpha expressing pJDB2 containing Aeromonas caviae A324R metallo-beta-lactamase gene by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID69960	Compound alone was evaluated for minimum inhibitory concentration against Escherichia coli A20107	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.
AID584985	Ratio of Inactivation rate constant for longer incubation time yield to Km for beta-lactamase TEM-1 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID351627	Drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 8 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID332500	Inhibition of Enterobacter cloacae P99 beta-lactamase assessed as inhibition of nitrocefin hydrolysis pre-incubated for 5 mins by microtiter plate assay	1994	Journal of natural products, May, Volume: 57, Issue:5	SB-202742, a novel beta-lactamase inhibitor isolated from Spondias mombin.
AID351625	Drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 4 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID1808873	Inhibition beta lactamase PDC-1 in Pseudomonas aeruginosa PAO1 using nitrocefin as substrate measured by 96 well microtitre plate
AID727643	Binding affinity to wild type Beta-lactamase SHV-1 in Escherichia coli DH10B assessed as melting temperature at 50 uM by circular dichroism analysis (Rvb = 54.2 degC)	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID377030	Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 after 24 hrs by disk diffusion assay	2005	Journal of natural products, Jan, Volume: 68, Issue:1	Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID1209457	Unbound Cmax in human plasma	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID332502	Inhibition of Staphylococcus aureus Russell beta-lactamase assessed as inhibition of nitrocefin hydrolysis pre-incubated for 5 mins by microtiter plate assay	1994	Journal of natural products, May, Volume: 57, Issue:5	SB-202742, a novel beta-lactamase inhibitor isolated from Spondias mombin.
AID1625569	Potentiation of meropenem-induced bactericidal activity against wild-type replicating Mycobacterium tuberculosis H37Rv assessed as decrease in MIC90 relative to control	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis.
AID1225759	Inhibition of Escherichia coli recombinant KPC-2 assessed as substrate nitrocefin degradation preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometric analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID377031	Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by disk diffusion assay	2005	Journal of natural products, Jan, Volume: 68, Issue:1	Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID326269	Inhibition of Escherichia coli TEM1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID351622	Drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 1.5 hr	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID351639	Unbound drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 1 hr	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID572898	Inhibition of Enterobacter cloacae Beta-lactamase AmpC	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor.
AID585192	Inhibition of Beta-lactamase GES-13 K104, N170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID351643	Unbound drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 4 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID563972	Activity of Klebsiella pneumoniae 05-560 beta-lactamase NDM-1 by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID374366	Antimicrobial activity against Escherichia coli DH5alpha by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID70244	Compound was evaluated for minimum inhibitory concentration in the presence of amoxicillin against Escherichia coli A20107	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.
AID727648	Antimicrobial activity against Escherichia coli DH10B expressing Beta-lactamase SHV K234R mutant by CLSI agar dilution method in presence of ampicillin	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID584976	Inhibition of beta-lactamase TEM- 1 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID727649	Antimicrobial activity against Escherichia coli DH10B expressing wild type Beta-lactamase SHV1 gene by CLSI agar dilution method in presence of ampicillin	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID351630	Unbound drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 1 hr	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID200260	Minimum inhibitory activity against Staphylococcus aureus A9606	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID351633	Unbound drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 3 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID332498	Inhibition of Escherichia coli JT4 beta-lactamase TEM1 assessed as inhibition of nitrocefin hydrolysis preincubated for 5 mins by microtiter plate assay	1994	Journal of natural products, May, Volume: 57, Issue:5	SB-202742, a novel beta-lactamase inhibitor isolated from Spondias mombin.
AID727647	Antimicrobial activity against Escherichia coli DH10B expressing Beta-lactamase SHV K234A mutant by CLSI agar dilution method in presence of ampicillin	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID558546	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P286 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1559308	Inhibition of bacterial KPC-2 using imipenem as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID517931	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae assessed as decrease in zone of inhibition at 30 ug by disk diffusion method in presence of clavulanic acid	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID377029	Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by disk diffusion assay	2005	Journal of natural products, Jan, Volume: 68, Issue:1	Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID558550	Antibacterial activity against Campylobacter jejuni isolate P338 harboring blaOXA-61::cat gene by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID727640	Binding affinity to Beta-lactamase SHV-1 K234R protein mutant in Escherichia coli DH10B assessed as change in secondary structure at 50 uM by circular dichroism analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID351620	Drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 12 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID572899	Inhibition of Beta-lactamase TEM-1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor.
AID43098	Beta-lactamase inhibitory activity from Bacillus fragilis A-22,695 and minimum protective concentration was reported	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID351626	Drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 6 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID555231	Inhibition of Acinetobacter genomosp. 3 isolate 195 ADC-18	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID332497	Inhibition of Escherichia coli K-12 beta-lactamase OXA1 assessed as inhibition of nitrocefin hydrolysis pre-incubated for 5 mins by microtiter plate assay	1994	Journal of natural products, May, Volume: 57, Issue:5	SB-202742, a novel beta-lactamase inhibitor isolated from Spondias mombin.
AID584983	Inhibition of beta-lactamase TEM-1 assessed as inactivation rate constant for longer incubation time yield of enzyme by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1225764	Inhibition of Escherichia coli recombinant CMY-2 assessed as substrate nitrocefin degradation preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometric analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID207623	Compound alone was evaluated for minimum inhibitory concentration against Staphylococcus aureus A15033	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.
AID377035	Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 after 24 hrs by disk diffusion assay	2005	Journal of natural products, Jan, Volume: 68, Issue:1	Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID374365	Antimicrobial activity against Escherichia coli DH5alpha expressing pIP19 containing Aeromonas caviae A324R metallo-beta-lactamase blaIMP-19 gene by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID351634	Unbound drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 4 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1559318	Inhibition of bacterial CMY-2 using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID43913	Inhibitory activity against Penicillinase from Staphylococcus aureus TH-14 using piperacillin (40 uM) as a substrate	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.
AID560135	Inhibition of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID285276	Inhibition of Escherichia coli BL21(DE3) beta-lactamase TEM36	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID495800	Inhibition of Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B carrying pSau1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID558556	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1730 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID372638	Inhibition of Escherichia coli DH10B beta-lactamase TEM-121 after 10 mins	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID351631	Unbound drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 1.5 hr	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1559310	Inhibition of bacterial OXA-48 using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID548269	Ratio of Ki for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237S mutant to Ki for Klebsiella pneumoniae wild type beta-lactamase KPC-2 by competitive assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID200259	Minimum inhibitory activity against Staphylococcus aureus A20309	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID372632	Ratio of IC50 for Escherichia coli DH5alpha beta-lactamase TEM-158 to IC50 for Escherichia coli DH5alpha beta-lactamase TEM-1	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID66646	Inhibitory concentration which is required to cause 50% inhibition of human leukocyte elastase (HLE) enzyme	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Inhibition of human leukocyte elastase. 1. Inhibition by C-7-substituted cephalosporin tert-butyl esters.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID351209	fTmax in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID372629	Inhibition of Escherichia coli CF0042 beta-lactamase TEM-35	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID727652	Inhibition of wild type Beta-lactamase SHV-1 in Escherichia coli DH10B by Henri-Michaelis-Menten steady state equation analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID558555	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1650 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID727650	Antimicrobial activity against Escherichia coli DH10B by CLSI agar dilution method in presence of ampicillin	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID326275	Inhibition of Escherichia coli K12 TEM1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID285274	Inhibition of Escherichia coli BL21(DE3) beta-lactamase TEM28	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID555229	Inhibition of Acinetobacter genomosp. 3 isolate 65 ADC-14	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID560136	Inhibition of recombinant beta-lactamase RTG3 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID351649	fCmax in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID558560	Antibacterial activity against bla gene-negative and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P854 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID394491	Inhibition of Escherichia coli beta-lactamase ACC4	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID584977	Inhibition of Enterobacter cloacae beta-lactamase P99 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID207800	Compound was evaluated for minimum inhibitory concentration in the presence of amoxicillin against Staphylococcus aureus A15033	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID548267	Inhibition of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237S mutant by competitive assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID1559321	Inhibition of bacterial IMP-1 using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID558554	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1618 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID69324	In vitro inhibition of Escherichia coli TEM-3 growth.	1998	Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21	Structure-based design of beta-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams.
AID541857	Antimicrobial activity against Escherichia coli ATCC 29522 carrying Edwardsiella ictaluri pM07-1 by microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.
AID297200	Inhibition of Enterobacter cloacae AmpC	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	4-Substituted trinems as broad spectrum beta-lactamase inhibitors: structure-based design, synthesis, and biological activity.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID531315	Activity of Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID43566	Inhibitory activity against Beta-lactamase type TEM2 (penicillinase) from Escherichia coli TEM2 using penicillin G (40 uM) as a substrate	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.
AID555230	Inhibition of Acinetobacter genomosp. 3 isolate 103 ADC-16	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID351644	Unbound drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 6 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID548268	Inhibition of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237A mutant by competitive assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID351216	Tmax in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID43885	Inhibitory concentration was evaluated as concentration required for 50% inhibition of Pseudomonas aeruginosa 18SH Beta-lactamase	1998	Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21	Structure-based design of beta-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams.
AID52216	Inhibitory activity against cephalosporinase from Proteus vulgaris TH-147 using cephalexin (40 uM) as a substrate	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.
AID351437	Drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 3 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID584978	Inhibition of Pseudomonas aeruginosa beta-lactamase AmpC assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1225762	Inhibition of Escherichia coli recombinant TEM-10 assessed as substrate nitrocefin degradation preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometric analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID332499	Inhibition of Pseudomonas aeruginosa A beta-lactamase assessed as inhibition of nitrocefin hydrolysis preincubated for 5 mins by microtiter plate assay	1994	Journal of natural products, May, Volume: 57, Issue:5	SB-202742, a novel beta-lactamase inhibitor isolated from Spondias mombin.
AID519750	Inhibition of Klebsiella pneumoniae Beta-Lactamase SHV-1	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID351628	Drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 10 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID585187	Inhibition of Beta-lactamase GES-1 E104, G170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID727642	Binding affinity to Beta-lactamase SHV-1 K234R protein mutant in Escherichia coli DH10B assessed as melting temperature at 50 uM by circular dichroism analysis (Rvb = 48.2 degC)	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID209010	Time dependent inhibition of hydrolysis of nitrocefin after 5 min pre-incubation with TEM-1 beta-lactamase (class 1)	2004	Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10	Design and synthesis of bridged gamma-lactams as analogues of beta-lactam antibiotics.
AID531316	Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID43893	Minimum protective concentration against beta-lactamase Pseudomonas aeruginosa (18S-H strain)	1997	Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21	Cephalosporin 3'-phloroglucide esters and 7-(phloroglucidamido) cephalosporins as novel antibacterial agents.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID558562	Antibacterial activity against bla-positive and beta-lactamase-weakly positive Campylobacter coli isolate P1627 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID558553	Antibacterial activity against Campylobacter jejuni isolate P1093 harboring blaOXA-61::cat gene by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID351219	fAUC (0 to 24 hrs) in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID1559316	Inhibition of bacterial SHV-5 using cefotaxime as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID50709	The compound was tested for its inhibitory activity towards Class C beta-lactamase from Enterobacter cloacae 908R at 0.8 umol concentration	2002	Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6	Design, synthesis and bioactivity evaluation of tribactam beta lactamase inhibitors.
AID525578	Inhibition of Beta-lactamase OXA-14 expressed in Escherichia coli BL21 (DE3) by nitrocefin hydrolysis assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Penicillin sulfone inhibitors of class D beta-lactamases.
AID372639	Inhibition of Escherichia coli TO799 beta-lactamase TEM-125 after 10 mins	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID351629	Drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 12 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID44219	Inhibitory activity at beta-lactamase I from Bacillus cereus expressed as percent inhibition of beta-lactam hydrolysis at a concentration of 10.0 umol/L	2002	Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6	Design, synthesis and bioactivity evaluation of tribactam beta lactamase inhibitors.
AID519985	Inhibition of Klebsiella pneumoniae Beta-Lactamase SHV-55	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae.
AID64067	Minimum inhibitory activity against Escherichia coli A9675	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID326274	Inhibition of Escherichia coli K12 CARB1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1225761	Inhibition of Escherichia coli recombinant SHV-12 assessed as substrate nitrocefin degradation preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometric analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID558559	Antibacterial activity against bla gene-negative and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P843 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID585191	Inhibition of Beta-lactamase GES-6 K104, S170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID531313	Activity of Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID43741	Minimum protective concentration used to protect the compound against Klebsiella pneumoniae A20634 beta-lactamase catalyzed hydrolysis	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.
AID44220	Inhibitory activity at beta-lactamase I from Bacillus cereus expressed as percent inhibition of beta-lactam hydrolysis at a concentration of 100.0 umol/L	2002	Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6	Design, synthesis and bioactivity evaluation of tribactam beta lactamase inhibitors.
AID558544	Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1962 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID495801	Inhibition of carbapenem-resistant Klebsiella pneumoniae carbepenem-hydrolyzing beta-lactamase KPC-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID1559311	Inhibition of bacterial VIM-2 using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1209455	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID285277	Inhibition of Escherichia coli BL21(DE3) beta-lactamase TEM1	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID377033	Antimicrobial activity against Escherichia coli ATCC 25922 after 24 hrs by disk diffusion assay	2005	Journal of natural products, Jan, Volume: 68, Issue:1	Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID496597	Ratio of Kinact to Km for Escherichia coli DH10B beta-lactamase KPC-2	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID548266	Inhibition of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 by competitive assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID525579	Inhibition of Beta-lactamase OXA-10 expressed in Escherichia coli BL21 (DE3) by nitrocefin hydrolysis assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Penicillin sulfone inhibitors of class D beta-lactamases.
AID496596	Ratio of Kcat to Kinact for Escherichia coli DH10B beta-lactamase KPC-2	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID332501	Inhibition of Proteus mirabilis C889 beta-lactamase assessed as inhibition of nitrocefin hydrolysis preincubated for 5 mins by microtiter plate assay	1994	Journal of natural products, May, Volume: 57, Issue:5	SB-202742, a novel beta-lactamase inhibitor isolated from Spondias mombin.
AID351647	Unbound drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 12 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID495659	Inhibition of Pseudomonas aeruginosa 531 beta-lactamase BEL-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID558563	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter coli isolate P1826 by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID372631	Ratio of IC50 for Escherichia coli DH5alpha beta-lactamase TEM-158 to IC50 for Escherichia coli DH5alpha beta-lactamase TEM-12	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID567285	Binding affinity to Acinetobacter baumannii ADC-11 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID585190	Inhibition of Beta-lactamase GES-5 E104, S170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID19101	Half life at a pH of 9 and temperature 37 degree	2004	Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10	Design and synthesis of bridged gamma-lactams as analogues of beta-lactam antibiotics.
AID351220	AUC (0 to 24 hrs) in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID162939	In vitro inhibition of Pseudomonas aeruginosa 18SH growth.	1998	Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21	Structure-based design of beta-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams.
AID531318	Ratio of Kcat to Km for Escherichia coli beta-lactamase VIM-1 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID351215	fCmax in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID207624	Compound alone was evaluated for minimum inhibitory concentration against Staphylococcus aureus A9606	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.
AID519984	Inhibition of Klebsiella pneumoniae Beta-Lactamase SHV-1	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae.
AID200258	Minimum inhibitory activity against Staphylococcus aureus A15091	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID372630	Inhibition of Escherichia coli DH5alpha beta-lactamase TEM-1	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID558541	Antibacterial activity against Campylobacter jejuni isolate P270 harboring blaOXA-61::cat gene by NCCLS agar doubling dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID727646	Antimicrobial activity against Escherichia coli DH10B expressing Beta-lactamase SHV K234X mutant by CLSI agar dilution method in presence of ampicillin	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID332496	Inhibition of Escherichia coli K-12 beta-lactamase PSE-4 assessed as inhibition of nitrocefin hydrolysis preincubated for 5 mins by microtiter plate assay	1994	Journal of natural products, May, Volume: 57, Issue:5	SB-202742, a novel beta-lactamase inhibitor isolated from Spondias mombin.
AID563976	Activity of Klebsiella pneumoniae 05-560 beta-lactamase VIM2 by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID495653	Inhibition of Pseudomonas luteola LAM Beta-lactamase LUT-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID1559309	Inhibition of bacterial AmpC using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID351439	Drug concentration in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 6 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID1225763	Inhibition of Escherichia coli recombinant P99 assessed as substrate nitrocefin degradation preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometric analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID541856	Antimicrobial activity against florfenicol-resistant Edwardsiella ictaluri M07-1 by microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.
AID64066	Minimum inhibitory activity against Escherichia coli A21223	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID422501	Ratio of IC50 for beta-lactamase TEM-1 over IC50 for Carnobacterium divergens BM4489 penicillinase Cad-1	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID351650	AUC (0 to 24 hrs) in beta lactamase-positive Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID207801	Compound was evaluated for minimum inhibitory concentration in the presence of amoxicillin against Staphylococcus aureus A9606	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.
AID44218	Inhibitory activity at beta-lactamase I from Bacillus cereus expressed as percent inhibition of beta-lactam hydrolysis at a concentration of 1.0 umol/L	2002	Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6	Design, synthesis and bioactivity evaluation of tribactam beta lactamase inhibitors.
AID351621	Drug concentration in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model dosed as amoxicillin-clavulanic acid at simulated human serum concentration of 2000/125 mg, po bid after 1 hr	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	366 (21.67)	18.7374
1990's	445 (26.35)	18.2507
2000's	412 (24.39)	29.6817
2010's	354 (20.96)	24.3611
2020's	112 (6.63)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	212 (11.77%)	5.53%
Reviews	112 (6.22%)	6.00%
Case Studies	200 (11.10%)	4.05%
Observational	10 (0.56%)	0.25%
Other	1,267 (70.35%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (172)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Pharmacokinetics and Safety of Ticarcillin-clavulanate in Infants [NCT01229046]	Phase 1	0 participants (Actual)	Interventional	2010-09-30	Withdrawn(stopped due to No enrollment occured. Subjects will be enrolled under a new protocol.)
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Pilot Study to Assess the Efficacy and Safety of Clavulanic Acid vs. Placebo for the Treatment of Cocaine Use Disorder [NCT05562349]	Phase 2	65 participants (Anticipated)	Interventional	2023-05-03	Recruiting
The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial [NCT02800785]		1,552 participants (Actual)	Interventional	2016-05-31	Completed
Oral Antibiotics to Prevent Infection and Wound Dehiscence After Obstetric Perineal Tear - a Double-blinded Placebo Controlled Randomized Trail [NCT05830162]	Phase 4	442 participants (Anticipated)	Interventional	2023-03-21	Recruiting
A Randomized, Double-blind, Multicenter Trial to Evaluate the Safety and Efficacy of Sequential (Intravenous, Oral) Moxifloxacin Versus Comparator in Pediatric Subjects With Complicated Intra-abdominal Infection [NCT01069900]	Phase 3	458 participants (Actual)	Interventional	2010-07-21	Completed
Prospective Randomized Clinical Trial Comparing Efficacy Surgical Versus Medical Treatment of Osteomyelitis in Diabetic Foot Ulcers [NCT01137903]		88 participants (Anticipated)	Interventional	2010-04-30	Recruiting
Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers [NCT02381470]	Phase 2	58 participants (Actual)	Interventional	2019-02-11	Completed
A Phase 2 Trial to Evaluate the Early Bactericidal Activity and Safety of Meropenem With Amoxicillin/Clavulanate Plus Either Pyrazinamde or Bedaquiline in Adults With Newly Diagnosed Rifampicin-susceptible Pulmonary Tuberculosis [NCT04629378]	Phase 2	22 participants (Actual)	Interventional	2020-08-17	Completed
A Phase IV Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate Short Course vs.Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP) [NCT02891915]	Phase 4	385 participants (Actual)	Interventional	2016-12-02	Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]	Early Phase 1	11 participants (Actual)	Interventional	2014-03-06	Terminated(stopped due to Not enough patient enrollment and lack of staffing)
A New Antibiotic Prophylaxis Regimen to Prevent Bacteremia Following Dental Procedures [NCT02115776]		266 participants (Actual)	Interventional	2014-01-31	Completed
COMPARISON OF CLINICAL EFFICACY OF COMBINATION Amoxycillin Plus Clavulanic Acid and Oxacillin Plus Ceftriaxone for HOSPITAL TREATMENT OF COMMUNITY Acquired PNEUMONIA IN CHILDREN : A Randomized Clinical Study [NCT01166932]	Phase 4	104 participants (Actual)	Interventional	2005-04-30	Completed
The Impact of Antibiotic Prophylaxis on Incidence of Post-bronchoscopy Fever and Change of Serum Cytokines [NCT01089218]	Phase 4	241 participants (Actual)	Interventional	2008-04-30	Completed
Pharmacokinetics and Pleural Fluid Penetration of Amoxicillin and Clavulanic Acid in Patients With Pleural Infections [NCT04350502]		11 participants (Actual)	Interventional	2020-04-04	Completed
Prospective Randomized Clinical Study: Role of Platelet Rich Fibrin (PRF) in the Tooth Extraction Site in the Prevention of Jaw Osteonecrosis on Patients Under Bisphosphonates Therapy [NCT02198001]		100 participants (Anticipated)	Interventional	2014-01-31	Recruiting
Pneumonia in Children: Aetiology, Ideal Antibiotic Duration, Quality of Life [NCT02258763]	Phase 4	19 participants (Actual)	Interventional	2014-11-30	Completed
An Open-Label, Single-Dose, Two-Way Crossover Bioequivalence Study of Two Oral Suspension Formulations of Amoxicillin/Clavulanate Potassium, 600/42.9 mg/5 mL in Healthy Subjects Under Fasting Conditions [NCT00840099]	Phase 1	48 participants (Actual)	Interventional	2002-08-31	Completed
Randomized, 2-Way Crossover, Bioequivalence Study of Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets and AUGMENTIN® 400 mg-57 mg Chewable Tablets Administered as 1 x 400 mg-57 mg Chewable Tablet in Healthy Subjects Under Fed Conditions [NCT00836901]	Phase 1	52 participants (Actual)	Interventional	2003-09-30	Completed
Evaluation of the Efficacy of an Antibiotic Combined With Standard Treatment in Severe Alcoholic Hepatitis [NCT02281929]	Phase 3	297 participants (Actual)	Interventional	2015-06-13	Completed
Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis [NCT03625739]		800 participants (Anticipated)	Observational [Patient Registry]	2018-07-01	Recruiting
Study Of The Antibiotic Role In Post Tonsillectomy Complications [NCT03491085]	Phase 1/Phase 2	200 participants (Anticipated)	Interventional	2018-05-15	Not yet recruiting
Oral Versus Intravenous Antibiotics for the Management of the Osteomyelitis of the Jaws: An Open-Label Non-Inferiority Single-Arm Clinical Trial [NCT05867654]		100 participants (Anticipated)	Observational	2023-11-01	Not yet recruiting
An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following [NCT02783404]	Phase 4	40 participants (Actual)	Interventional	2017-02-27	Terminated(stopped due to Significant results (no control neither amoxicillin new arms needed))
Antibiotic PRophylAxis Based on infeCTIve Risk in Cardiac Implantable Electronic Device - PRACTICE Study [NCT04736979]		1,044 participants (Actual)	Observational	2017-01-01	Completed
Is Combination Antibiotic Therapy Superior to Monotherapy in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease [NCT04879030]	Phase 2/Phase 3	170 participants (Actual)	Interventional	2020-01-01	Completed
Рrospective Multicenter Randomized 3 Phase Study Evaluating the Role of Prolonged Antibiotic Prophylaxis as a Measure to Reduce the Incidence of Postoperative Complications After Radical Cystectomy With ERAS Protocol [NCT05392634]	Phase 3	98 participants (Anticipated)	Interventional	2022-02-02	Recruiting
An Open-Label, Single-Dose, Two-Way Crossover Bioequivalence Study of Two Oral Suspension Formulations of Amoxicillin/Clavulanate Potassium, 600/42.9 mg/5 mL in Healthy Subjects, Under Fed Conditions [NCT00840840]	Phase 1	48 participants (Actual)	Interventional	2002-08-31	Completed
Shortened Antibiotic Therapy for Febrile Urinary Tract Infection (UTI) in Childhood: a Multicenter Randomized Controlled Trial [NCT04400110]	Phase 4	154 participants (Actual)	Interventional	2020-06-08	Completed
A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Sanfetrinem Cilexetil Administered Orally to Adults With Newly Diagnosed, Smear-Positive, Rifampicin-Susceptible Pulmonary Tuberculosis [NCT05388448]	Phase 2	105 participants (Anticipated)	Interventional	2022-04-21	Recruiting
DIABOLO Trial: A Multicenter Randomized Clinical Trial Investigating the Cost-effectiveness of Treatment Strategies With or Without Antibiotics for Uncomplicated Acute Diverticulitis. [NCT01111253]	Phase 4	533 participants (Anticipated)	Interventional	2010-05-31	Active, not recruiting
Antibiotic-associated Gastrointestinal Side Effects and the Role of the Gut Microbiome [NCT04156555]	Phase 4	30 participants (Actual)	Interventional	2019-08-01	Completed
Effects of Phenoximethylpenicillin, Amoxicillin and Amoxicillin-clavulanic Acid on the Gut Microbiota of Healthy Volunteers: a Randomized Clinical Trail [NCT04084106]	Phase 4	104 participants (Actual)	Interventional	2019-09-10	Completed
Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868]	Phase 4	135 participants (Anticipated)	Interventional	2023-08-04	Enrolling by invitation
Randomized, 2-Way Crossover, Bioequivalence Study of Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets and AUGMENTIN® 400 mg-57 mg Chewable Tablets Administered as 1 x 400 mg-57 mg Chewable Tablet in Healthy Subjects Under Fasting Conditions [NCT00835705]	Phase 1	52 participants (Actual)	Interventional	2003-09-30	Completed
Prevention of Early Ventilator-associated Pneumonia With Antibiotic Therapy in Patients Treated With Mild Therapeutic Hypothermia After Cardiac Arrest. [NCT02186951]	Phase 3	197 participants (Actual)	Interventional	2014-08-18	Completed
An Open Label, Single Arm Study, to Evaluate the Pharmacokinetics of LP-001 Oral Suspension in Children With a Bacterial Infection [NCT05584683]	Phase 1	24 participants (Anticipated)	Interventional	2022-12-12	Not yet recruiting
Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients [NCT03120663]		120 participants (Anticipated)	Observational	2016-11-30	Recruiting
Home Intravenous Versus Oral Antibiotics Following Appendectomy for Perforated Appendicitis in Children, a Randomized Controlled Trial [NCT02724410]		82 participants (Actual)	Interventional	2011-01-31	Completed
Clindamycin Versus Amoxicillin With Clavulanic Acid in Prevention of Early Dental Implants Failure [NCT04980170]	Early Phase 1	100 participants (Anticipated)	Interventional	2021-11-01	Not yet recruiting
Use of Perioperative Antibiotics in Endoscopic Sinus Surgery [NCT03369717]	Phase 4	400 participants (Anticipated)	Interventional	2018-08-01	Suspended(stopped due to Expired IRB approval since 05/07/2020)
Antibiotic Dosing in Pediatric Intensive Care [NCT02456974]		640 participants (Anticipated)	Observational [Patient Registry]	2012-05-31	Recruiting
Phase 2/3 Evaluation of Three Lactobacilli Strains Isolated From Human Milk for the Treatment of Infectious Mastitis During the Lactation Period [NCT00716183]	Phase 2/Phase 3	300 participants (Actual)	Interventional	2008-07-31	Completed
Pharmacokinetic Study of the Amoxicillin / Clavulanic Acid Association to Optimize Dosage Among Obese Adults (PHACO) [NCT02571959]	Phase 1/Phase 2	36 participants (Actual)	Interventional	2015-07-24	Completed
Early Bactericidal Activity of Cephalexin and Amoxicillin-clavulanate for Susceptible Tuberculosis - BLAST 1 Trial [NCT05664568]	Phase 2	30 participants (Anticipated)	Interventional	2023-03-15	Recruiting
Non Operative Treatment for Acute Appendicitis: Study on Efficacy and Safety of Antibiotic Treatment (Amoxicillin and Clavulanic Acid) in Patients With Right Sided Lower Abdominal Pain [NCT01096927]	Phase 4	160 participants (Actual)	Interventional	2010-01-31	Completed
Efficacy of Antimicrobials in Young Children With Acute Otitis Media (AOM) [NCT00377260]	Phase 4	291 participants (Actual)	Interventional	2006-11-30	Completed
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707]	Phase 3	10,000 participants (Anticipated)	Interventional	2016-04-11	Recruiting
Benefit of a Single Preoperative Dose of Antibiotics in a Sub-Saharan District Hospital: Minimal Input, Massive Impact [NCT00801099]		276 participants (Actual)	Interventional	2004-12-31	Completed
Randomized Controlled Trial Comparing Long and Short Duration of Antibiotic Prophylaxis for Patients Undergoing Sinus Lift Surgery [NCT02764710]	Phase 3	250 participants (Anticipated)	Interventional	2016-05-31	Not yet recruiting
Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid [NCT00603317]	Phase 4	13 participants (Actual)	Interventional	2008-03-31	Completed
A Phase IIIB/IV Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets vs. Amoxicillin-Clavulanate for the Treatment of Subjects With Acute Bacterial Sinusitis [NCT00644553]	Phase 3	437 participants (Actual)	Interventional	2003-05-31	Completed
Initial Non-operative Treatment Strategy Versus Appendectomy Treatment Strategy for Simple Appendicitis in Children Aged 7-17 Years Old - Antibiotics Versus Primary Appendectomy in Children With Simple Appendicitis: APAC Study [NCT02848820]	Phase 4	302 participants (Actual)	Interventional	2016-12-31	Active, not recruiting
A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Amoxicillin/Clavulanate Potassium (Augmentin ES-600 Trademark) for the Treatment of Acute Otitis Media in Children Undergoing Diagnostic Tympanocentesis [NCT00643292]	Phase 3	902 participants (Actual)	Interventional	2003-01-31	Completed
Prophylaxis of Surgical Wound Infection in Incisional Hernia Repair With Topical Antibiotics (PROTOP-PAR) [NCT05508152]	Phase 3	260 participants (Actual)	Interventional	2021-02-01	Completed
Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis [NCT06076304]	Phase 4	144 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media [NCT02567825]		250 participants (Actual)	Interventional	2015-11-30	Completed
Prospective, Multicenter, Randomized, Double Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of Moxifloxacin 400 mg OD for 7 Days Versus a Standard Antibiotic Therapy for 10 Days in the Treatment of Acute Bacterial Rhino Sinusitis [NCT00493038]	Phase 4	293 participants (Actual)	Interventional	2006-02-28	Terminated(stopped due to The study was prematurely terminated due to slow enrollment beyond the planned study timelines.)
Antibiotic Therapy is Not Necessary to Implant Totally Implantable Venous Access Devices: Randomized Prospective Study [NCT00665873]	Phase 4	100 participants (Actual)	Interventional	2004-01-31	Completed
MAESTRAL - A Prospective, Multinational, Multicenter, Randomized, Double Blind, Double Dummy, Controlled Study Comparing the Efficacy and Safety of Moxifloxacin to That of Amoxicillin Clavulanic Acid for the Treatment of Subjects With Acute Exacerbations [NCT00656747]	Phase 4	1,372 participants (Actual)	Interventional	2008-03-31	Completed
A Phase 2 Randomized, Double-blind, Double-dummy Efficacy, Safety And Tolerability Study Of Iv Sulopenem With Switch To Oral Pf-03709270 Compared To Ceftriaxone With Step Down To Amoxicillin/Clavulanate Potassium (Augmentin) In Subjects With Community Acq [NCT00797108]	Phase 2	35 participants (Actual)	Interventional	2009-01-31	Completed
Supportive Care and Antibiotics for Severe Pneumonia Among Hospitalized Children [NCT04041791]	Phase 3	4,392 participants (Anticipated)	Interventional	2019-08-19	Recruiting
Randomized, Open - Label, 2 - Way Crossover, Bioequivalence Study of Amoxicillin-Clavulanic Acid 600mg - 42.9 mg/ 5 mL Oral Suspension and Augmentin ES - 600 (Reference) Following a 600 mg - 42.9 mg Dose in Healthy Subjects Under Fasting Conditions [NCT00778414]		48 participants (Actual)	Interventional	2006-06-30	Completed
[NCT04082598]	Phase 4	165 participants (Actual)	Interventional	2016-10-01	Completed
A National, Prospective, Randomized, Open Label Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin vs IV Ceftriaxone + IV Azithromycin Followed by PO Amoxicilline/Clavulanate and PO Clarithromycin in Subjects With Community-acquired Pneumonia [NCT00717561]	Phase 3	60 participants (Actual)	Interventional	2008-02-29	Completed
Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in Febrile UTIs Caused by ESBL-producing Enterobacterales (PACUTI) [NCT05224401]	Phase 3	330 participants (Anticipated)	Interventional	2023-05-29	Recruiting
Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children [NCT01166945]		98 participants (Actual)	Interventional	2010-11-30	Completed
A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infections [NCT01110408]	Phase 3	41 participants (Actual)	Interventional	2010-12-31	Terminated(stopped due to Trial terminated early per business decision)
A Prospective, Randomized, Double Dummy, Double Blind, Multinational, Multicenter Trial Comparing the Safety and Efficacy of Sequential (Intravenous/Oral) Moxifloxacin 400 mg OD to Intravenous Piperacillin/Tazobactam 4.0/0.5 g Every 8 Hours Followed by Or [NCT00402727]	Phase 3	813 participants (Actual)	Interventional	2006-09-30	Completed
A Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of the Efficacy, Tolerability, and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Amoxicillin/Clavulanate for Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Ad [NCT05584657]	Phase 3	2,229 participants (Actual)	Interventional	2022-10-18	Active, not recruiting
Situations That do Not Require Antibiotics for Acute Exacerbations of Mild-to-moderate Chronic Obstructive Pulmonary Disease [NCT00495586]	Phase 4	318 participants (Actual)	Interventional	2007-10-31	Completed
Randomized, Multicenter, Phase III, Controlled Clinical Trial, to Demonstrate the no Inferiority of Reduced Antibiotic Treatment vs a Broad Spectrum Betalactam Antipseudomonal Treatment in Patients With Bacteremia by Enterobacteriaceae [NCT02795949]	Phase 3	344 participants (Actual)	Interventional	2016-10-31	Completed
Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children: Prospective, Multi-center, Randomize, Parallel Group Placebo Controlled Clinical Trial [NCT02765217]	Phase 4	1,325 participants (Actual)	Interventional	2017-06-01	Completed
Randomized, Open-Label, 2 - Way Crossover, Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg- 42.9 mg/ 5 mL Oral Suspension and Augmentin ES-600 (Reference) Following a 600 mg- 42.9 mg Dose in Healthy Subjects Under Fed Conditions. [NCT00778544]		48 participants (Actual)	Interventional	2006-06-30	Completed
Multiple-dose Pharmacokinetics of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid During Haemodialysis in Longterm Haemodialysis Patients [NCT02007603]	Phase 3	16 participants (Actual)	Interventional	2013-08-31	Completed
A Comparison Study Between Cefdinir and Amoxicilline/Clavulanate in Patients With Acute Sinusitis and Assessment of Quality of Life (QOL) [NCT00147914]	Phase 4	100 participants (Actual)	Interventional	2005-02-28	Completed
A Prospective, Randomized Trial of Antibiotic Duration in Post-appendectomy Abscess [NCT03795194]	Phase 4	12 participants (Actual)	Interventional	2019-05-01	Terminated(stopped due to Due to low enrollment.)
Exploratory Pilot Studies to Demonstrate Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics [NCT03755765]	Early Phase 1	66 participants (Actual)	Interventional	2019-07-23	Completed
A Phase IA Open Label Pharmaco- Magnetic Resonance Spectrography (MRS) Study of Clavulanic Acid Daily Repeated Administration in Remitted Cocaine Use Disorder Subjects [NCT03986762]	Phase 1	9 participants (Actual)	Interventional	2019-03-12	Completed
Perianal Abscess Recurrence and Fistula Formation: Antibiotics Following Incision and Drainage Trial - (PARFAIT) A Vanguard Randomized Controlled Trial [NCT04549311]	Phase 3	15 participants (Actual)	Interventional	2021-11-18	Active, not recruiting
A Phase 2a Study of the Early Bactericidal Activity of Rifampin (RIF) in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampin-resistant or Rifampin-susceptible Pulmonary Tuberculosis [NCT03174184]	Phase 2	112 participants (Actual)	Interventional	2017-08-23	Completed
Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy: Comparison of 8 Weeks Standard Therapy (Rifampicin Plus Clarithromycin) vs. 4 Weeks Standard Plus Amoxicillin/Clavulanate Therapy [RC8 vs. RCA4] [NCT05169554]	Phase 2	140 participants (Anticipated)	Interventional	2021-12-01	Recruiting
CAT BITE Antibiotic Prophylaxis and Durations for the Hand/Forearm (CATBITE): A Prospective, Randomized, Placebo-controlled, Double-blinded, Clinical Trial [NCT05846399]	Phase 4	72 participants (Anticipated)	Interventional	2023-09-07	Recruiting
A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Meropenem in Hospitalized Children With Complicated Intra-Abdominal Infections [NCT01110382]	Phase 3	41 participants (Actual)	Interventional	2010-12-31	Terminated(stopped due to Trial terminated early per business decision)
Does Adjuvant Antibiotic Treatment After Drainage of Anorectal Abscess Prevent the Development of Anal Fistulae? A Prospective Randomized, Placebo Controlled, Double Blind, Multi-Center Clinical Study [NCT01012843]		151 participants (Actual)	Interventional	2005-09-30	Completed
Antibiotic Treatment Versus no Antibiotics in the Postoperative Acute Cholecystitis Low and Moderately Severe [NCT01015417]	Phase 3	414 participants (Actual)	Interventional	2010-05-31	Completed
Open-label Comparative Safety and Efficacy Study of Levofloxacin and Amoxicillin Clavulanic Acid in Patients With Acute ,Bacterial Rhinosinusitis [NCT02712502]		100 participants (Actual)	Observational	2014-09-30	Completed
Multicentre Controlled, Randomized Clinical Trial to Compare the Efficacy and Safety of Ambulatory Treatment of Mild Acute Diverticulitis Without Antibiotics With the Standard Treatment With Antibiotics [NCT02785549]	Phase 4	480 participants (Actual)	Interventional	2016-11-30	Completed
Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media) [NCT01406275]		363 participants (Actual)	Observational	2008-01-31	Completed
A Multicenter Randomized Controlled Trial of Antibiotic Treatment in Children With Urinary Tract Infections: Oral Amoxicillin/Clavulanic Acid vs Initial iv Ceftriaxone. [NCT00161330]	Phase 3	440 participants	Interventional	2000-06-30	Terminated
Fast-track Absolute Neutrophil Count in Suspected Neutropenic Fever (The FRANCiS-NF Trial): A Single-centre, Pragmatic, Open-label, Randomised, Controlled Trial [NCT05393505]	Phase 4	344 participants (Anticipated)	Interventional	2022-10-24	Recruiting
Exploratory Pilot Studies to Demonstrate Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics [NCT04414722]	Early Phase 1	138 participants (Actual)	Interventional	2021-01-01	Completed
A Prospective, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Ertapenem Sodium ( MK0826) Versus Ticarcillin/Clavulanate in the Treatment of Hospital-Acquired Pneumonia, Complicated Intra-Abdomi [NCT00092170]	Phase 2	100 participants	Interventional	2002-03-31	Completed
Prophylactic Versus Clinically-driven Antibiotics in Comatose Survivors of Out-of-hospital Cardiac Arrest [NCT02899507]	Phase 4	60 participants (Actual)	Interventional	2013-09-30	Completed
The Efficiency of Postoperative Antibiotics in Orthognathic Surgery: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial [NCT02740647]		25 participants (Anticipated)	Interventional	2016-04-30	Not yet recruiting
Phase 1, Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Cocaine and Clavulanic Acid [NCT02563769]	Phase 1	10 participants (Actual)	Interventional	2016-10-24	Completed
Multicentre, Randomised, Double-blinded, Placebo-controlled Trial of Efficacy of Amoxicilline/Clavulanic Acid in Patients Affected by Tic Disorder Colonized by Group A Streptococcus [NCT01860300]		46 participants (Anticipated)	Interventional	2013-03-31	Recruiting
A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discha [NCT00445497]	Phase 3	400 participants (Anticipated)	Interventional	2007-07-31	Recruiting
The Effect of a Combination of Systemic Steroids and Antibiotics on Obstructive Sleep Apnea Syndrome in Children [NCT00456339]	Phase 4	4 participants (Actual)	Interventional	2006-07-31	Terminated(stopped due to Problems recruiting; patient relapse following treatment)
Efficacy and Cost Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Locally Advanced Head and Neck Cancer to Prevent Aspiration Pneumonia. A Randomized Phase II-III Study [NCT01598402]	Phase 2/Phase 3	106 participants (Anticipated)	Interventional	2011-12-31	Recruiting
Clinical Relevance of Middle Meatal Bacteriology During Acute Respiratory Infection in Children - Randomised, Double-Blinded Clinical Study [NCT00545961]	Phase 4	120 participants (Anticipated)	Interventional	2007-11-30	Not yet recruiting
A Phase 4 Double Blinded Study With Two Different Interventions, Each With Two Arms, to Evaluate the Clinical Efficacy of Antibiotics and the Role of Microbiology, Immunology and Genetics in Children Aged 9-36 Months With Chronic Wet Cough. [NCT06020716]	Phase 4	350 participants (Anticipated)	Interventional	2023-08-16	Recruiting
Effect of Preoperative, Single-dose Amoxicillin/Clavulanic Acid Combination on Postoperative Endodontic Pain in Patients With Symptomatic Apical Periodontitis: A Double-Blind Randomized Controlled Trial. [NCT03033147]		72 participants (Actual)	Interventional	2019-10-18	Completed
Phase 4 Efficacy Study of Antimicrobials in the Treatment of Acute Otitis Media in Young Children [NCT00299455]	Phase 4	320 participants (Anticipated)	Interventional	2006-03-31	Active, not recruiting
An Open, Non-comparative Study to Evaluate the Efficacy and Safety of AUGMENTIN 1gm (875mg Amoxicillin/125mg Clavulanic Acid) po q 12 Hours in the Treatment of Uncomplicated Skin and Soft Tissue Infections in Pakistan [NCT00343135]	Phase 4	195 participants (Actual)	Interventional	2004-12-31	Completed
A Prospective Randomized Multicentric Trial Comparing Amoxicillin/Clavulanate Potassium Therapy to Appendectomy for Acute Non Complicated Appendicitis [NCT00135603]		243 participants (Actual)	Interventional	2004-02-29	Completed
Oral Amoxicillin-clavulanate in Treating Acute Otitis Media in Children: Randomized Double-blind Placebo-controlled Study Including Daily Monitoring With Tympanometry [NCT01244581]	Phase 3	84 participants (Actual)	Interventional	1999-09-30	Completed
Evaluation of National Guidelines for Acute Sinusitis [NCT00132275]		240 participants (Anticipated)	Interventional	2003-11-30	Completed
eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce Clinically Relevant PostOperative Pancreatic Fistula: A Phase 2 Randomized Control Trial (X-POPF) [NCT05753735]	Phase 2	96 participants (Anticipated)	Interventional	2023-12-20	Recruiting
Bacteriological Study of Acute Follicular Tonsillitis in Patients Attending the ENT Outpatient Clinic of Assiut University Hospital [NCT04321733]		66 participants (Anticipated)	Observational	2020-04-30	Not yet recruiting
Effectiveness of Maxillary Sinus Saline Irrigation in Conjunction With Systemic Antibiotic Therapy Versus Systemic Antibiotic Therapy Alone in the Management of Chronic Rhinosinusitis, a Prospective Randomized Controlled Trial [NCT00335309]		50 participants (Actual)	Interventional	2005-10-31	Completed
Phase 3 Study of Antibiotic Prophylaxis Use Prior Emergent Surgery, Because of Acute Appendicitis [NCT01524081]	Phase 3	187 participants (Actual)	Interventional	2008-07-31	Completed
A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With Community-acquired Bacterial Pneumonia Requiring Hospital [NCT01530763]	Phase 2/Phase 3	161 participants (Actual)	Interventional	2012-09-30	Completed
[NCT00042718]	Phase 3	659 participants (Actual)	Interventional	2001-11-30	Completed
A Multicenter, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Levofloxacin in the Treatment of Children Who Have Recurrent and/or Persistent Acute Otitis Media [NCT00051753]	Phase 3	1,643 participants (Actual)	Interventional	2002-11-30	Completed
A Phase 2b, Multicenter, Randomized, Double Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Short-Course Antimicrobial Therapy for Young Children With Acute Otitis Media (AOM) and Impact on Antimicrobial Resistance [NCT01511107]	Phase 2	520 participants (Actual)	Interventional	2012-01-31	Terminated(stopped due to The primary objective of the study was met.)
Standard vs. Biofilm Susceptibility Testing in CF [NCT00153634]		75 participants (Actual)	Interventional	2004-03-31	Completed
Oral Empirical Therapy of Fever in Low-Risk Neutropenic Cancer Patients: A Prospective, Double-Blind, Randomized, Multicenter Trial Comparing Monotherapy (Single Daily Dose Moxifloxacin) With Combination Therapy (Ciprofloxacin Plus Amoxicillin/Clavulanic [NCT00062231]		351 participants (Actual)	Interventional	2002-04-30	Terminated(stopped due to low accrual)
Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media [NCT02630992]	Phase 3	112 participants (Actual)	Interventional	2015-12-31	Completed
Higher Versus Standard Dose of Amoxicillin-clavulanate in Pediatric Protracted Bacterial Bronchitis: a Randomized Controlled Study. [NCT04378231]		100 participants (Anticipated)	Interventional	2020-05-31	Not yet recruiting
The Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections [NCT01507974]		220 participants (Actual)	Interventional	2012-01-16	Completed
Continuous-infusion Anti-pseudomonal β-lactams for the Treatment of Acute, Infective Pulmonary Exacerbations in Cystic Fibrosis [NCT01667094]	Phase 4	50 participants (Actual)	Interventional	2012-09-30	Active, not recruiting
The Use of Prophylactic Antibiotics in Endoscopy Sinus Surgery for Chronic Rhinosinusitis With or Without Polyp: A Randomized, Double-blind Clinical Trial [NCT03809312]	Phase 4	134 participants (Anticipated)	Interventional	2019-08-14	Recruiting
A Third Phase, Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diver [NCT01733966]	Phase 3	100 participants (Actual)	Interventional	2010-05-31	Terminated(stopped due to difficulties to recruit patients who suffer from this pathology)
Bacteriology and Sputum and Systemic Inflammation in Steady-state, Acute Exacerbation and Recovery of Bronchiectasis [NCT01761214]		80 participants (Anticipated)	Interventional	2012-09-30	Recruiting
Bioequivalence Study of an Amoxicillin-Clavulanic Acid Suspension Preparation. Cross-over, Randomized, Single Dose, Two Treatments, Two Periods and Two Sequences Trial in Fasting Conditions [NCT01772238]	Phase 1	35 participants (Actual)	Interventional	2011-03-22	Completed
Comparison of a Serum Procalcitonin (PRO-CT) Guided Treatment Plan With the Standard Guideline Recommended Antibiotic Treatment Plan for Patients Hospitalized With a Diagnosis of Exacerbation of COPD [NCT01125098]		183 participants (Actual)	Observational	2006-10-31	Completed
Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis: A Cluster Randomized Cluster Crossover Non-Inferiority Study. [NCT04803422]		2,631 participants (Anticipated)	Interventional	2021-05-01	Recruiting
Open Label, Randomized Pilot Study to Examine The Effects of the Probiotic Saccharomyces Boulardii, the Antibiotic Amoxicillin/Clavulanate and the Combination on the Gut Microbiota of Healthy Volunteers [NCT01473368]		53 participants (Actual)	Interventional	2012-04-30	Completed
A Multicenter, Open-Label Study To Assess The Efficacy And Safety Of Potassium Clavulanate/Amoxicillin (CVA/AMPC 1:14 Combination) In The Treatment Of Children With Acute Bacterial Rhinosinusitis [NCT01934231]	Phase 3	27 participants (Actual)	Interventional	2013-08-30	Completed
A Study to Determine PK Profiles of AUGMENTIN XR in Adolescents Weight at Least 40 kg Receiving Augmentin XR BID for 10 Days [NCT00354965]	Phase 1	52 participants (Actual)	Interventional	2006-01-19	Completed
Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate [NCT02340000]	Phase 4	315 participants (Actual)	Interventional	2014-11-18	Completed
Risk of Acute Liver Injury in Users of Antimicrobials in the HealthCore Integrated Research Database Population [NCT01434173]		1,299,056 participants (Actual)	Observational	2001-07-31	Completed
Pharmacokinetics of Antistaphylococcal Antibiotics in Infants [NCT01728363]	Phase 1	63 participants (Actual)	Interventional	2013-01-31	Completed
Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of Efiicacy, Tolerability & Safety of Sulopenem & Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro-metronidazole for Treatment of cIAI in Adults [NCT03358576]	Phase 3	674 participants (Actual)	Interventional	2018-09-18	Completed
A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia [NCT01110421]	Phase 3	7 participants (Actual)	Interventional	2010-12-31	Terminated(stopped due to Trial terminated early per business decision)
Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics [NCT05761080]	Phase 4	158 participants (Anticipated)	Interventional	2021-04-22	Recruiting
A Phase 2/3, Randomized, Open-Label, Multi-center Study to Determine the Safety and Efficacy of Solithromycin in Adolescents and Children With Suspected or Confirmed Community-Acquired Bacterial Pneumonia [NCT02605122]	Phase 2/Phase 3	97 participants (Actual)	Interventional	2016-04-30	Terminated(stopped due to Development not proceeding)
Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: a Randomized Controlled Study -DALFEN Study [NCT03003273]	Phase 3	142 participants (Anticipated)	Interventional	2017-01-31	Terminated(stopped due to poor accrual)
A Multi-centre Double-blind Randomised Controlled Trial to Determine if a Longer Duration of Amoxicillin-clavulanic Acid (Compared to Shorter Duration) Improves Clinical Outcomes of Children Hospitalised With Community-acquired Pneumonia [NCT02783859]	Phase 4	314 participants (Anticipated)	Interventional	2016-06-30	Active, not recruiting
A Randomised Controlled Trial of Continuing Immunoglobulin Therapy, or Stopping With or Without Prophylactic Antibiotics, on Infection Rate in Patients With Acquired Hypogammaglobulinemia Secondary to Haematological Malignancies. [NCT05678621]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2023-01-31	Not yet recruiting
Comparison of Two Lengths of Treatment in Early-onset Ventilated Associated Pneumonia [NCT01559753]	Phase 4	225 participants (Actual)	Interventional	1998-01-31	Completed
Duration of Postoperative Antibiotic Prophylaxis in Facial Fractures (Mandibular Fractures, Zygomaticoorbital Fractures, Isolated Orbital Blow-out Fractures and LeFort I/II/III Fractures): 1 Day vs. 5 Days: a Prospective, Randomized, Double Blind and Plac [NCT01583062]	Phase 4	217 participants (Actual)	Interventional	2006-01-31	Terminated(stopped due to Limited number of patients)
Effect of Antimicrobial Treatment of Acute Otitis Media on the Intestinal Microbiome in Children: A Randomized Controlled Trial [NCT02935374]	Phase 4	73 participants (Actual)	Interventional	2016-11-30	Completed
A Study to Assess the Safety, Tolerability and Efficacy of OP0201 as an Adjunct Treatment for Acute Otitis Media in Infants and Children Aged 6 to 24 Months [NCT03818815]	Phase 2	103 participants (Actual)	Interventional	2019-02-21	Completed
Acupuncture and Herbal Treatment of Chronic HIV Sinusitis [NCT00002149]		40 participants	Interventional		Completed
Antibiotic Prophylaxis in Critically Ill Patients After Suspected Aspiration [NCT05079620]	Phase 4	100 participants (Anticipated)	Interventional	2021-11-30	Recruiting
Efficacy of Antibiotics in Children With Acute Sinusitis: Which Subgroups Benefit? [NCT02554383]	Phase 3	515 participants (Actual)	Interventional	2016-02-29	Completed
Prospective, Phase 3, Randomized, Multi-center, Double-blind, Double-dummy Study of Efficacy, Tolerability & Safety of Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Treatment of cUTI in Adults [NCT03357614]	Phase 3	1,395 participants (Actual)	Interventional	2018-09-18	Completed
2-day Prophylactic Antibiotic is Effective in Transoral Endoscopic Thyroidectomy [NCT04268407]		60 participants (Actual)	Interventional	2020-02-26	Completed
Delineation of Therapeutic Potential and the Causal Relationship Between Vitamin D and Helicobacter Pylori (HP) Infection and Gastritis [NCT03142620]	Phase 3	96 participants (Anticipated)	Interventional	2015-03-31	Recruiting
Comparing Efficacy of Postoperative Antibiotic Use in Transoral Thyroidectomy: a Prospective Randomized Controlled Trial Study [NCT03295955]		50 participants (Anticipated)	Interventional	2017-09-04	Recruiting
Antibiotic Profile of Pathogenic Bacteria Isolated From Postsurgical Site Infections in Public Hospitals in Northern Jordan [NCT05106803]		24 participants (Actual)	Observational	2019-08-01	Completed
A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem, Administered Intravenously, Plus Amoxycillin/CA and Faropenem, Administered Orally, Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed, Smear-positi [NCT02349841]	Phase 2	46 participants (Actual)	Interventional	2014-09-30	Completed
A Phase 1B Double Blind, Placebo (PBO) Controlled, Pharmaco- Magnetic Resonance Spectroscopy (MRS) Inpatient Study of Clavulanic Acid (CLAV) 500, 750, 1000 mg Daily Repeated Administration in Early Remitted Cocaine Use Disorder Subjects [NCT04411914]	Phase 1	13 participants (Actual)	Interventional	2020-09-01	Completed
Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori. [NCT01575899]	Phase 4	208 participants (Actual)	Interventional	2007-12-31	Terminated(stopped due to Early termination due to efficacy)
Postoperative Healthcare Utilization in Adenotonsillectomy Patients With Postoperative Antibiotic Administration Compared to Patients Without Antibiotic Administration [NCT01561703]		58 participants (Actual)	Interventional	2012-03-31	Completed
Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract [NCT02021006]	Phase 3	292 participants (Actual)	Interventional	2013-12-31	Active, not recruiting
Prospective Randomized Clinical Trial Assessing the Efficacy of a Short Course of Intravenous Amoxicillin Plus Clavulanic Acid Followed by Oral Antibiotic in Patients With Uncomplicated Acute Diverticulitis [NCT00917592]	Phase 4	50 participants (Actual)	Interventional	2005-12-31	Completed
Prophylactic Antibiotics After Functional Endoscopic Sinus Surgery: a Randomized, Double-blind Placebo Controlled Trial [NCT01919411]	Phase 4	134 participants (Actual)	Interventional	2013-02-28	Completed
Phase 1 Study to Evaluate the Effect of Oral Administration of Tebipenem Pivoxil Hydrobromide on Normal Human Intestinal Microbiota in Healthy Volunteers [NCT04376554]	Phase 1	30 participants (Actual)	Interventional	2020-02-10	Completed
Azithromycin With Amoxicillin/Clavulanate Versus Amoxicillin/Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA): a Superiority Open-label Randomized Controlled Trial [NCT04363060]	Phase 3	104 participants (Anticipated)	Interventional	2020-04-30	Not yet recruiting
PROTOP: Study of the Efficacy of Topical Antibiotherapy in the Prophylaxis of Incisional Surgical Localization Infection in Colorectal Surgery [NCT03574090]	Phase 4	268 participants (Actual)	Interventional	2020-10-20	Completed
Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis [NCT00462020]		102 participants (Actual)	Interventional	2007-03-31	Completed
Effect of Amoxicillin/Clavulanic Acid Combination on Postoperative Endodontic Pain in Patients With Symptomatic Apical Periodontitis: A Randomized Controlled Trial [NCT03007342]		78 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial. [NCT04698057]	Phase 3	0 participants (Actual)	Interventional	2022-03-01	Withdrawn(stopped due to No enrolment due to Covid-19)
Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single Doses of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers [NCT02393586]	Phase 1	43 participants (Actual)	Interventional	2015-02-28	Completed
An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction [NCT03713424]	Phase 2	30 participants (Anticipated)	Interventional	2019-03-26	Recruiting
Intravenous to Oral Antibiotic Switch Therapy for Probable Neonatal Bacterial Infections: Clinical Efficacy, Safety and Cost-effectiveness [NCT03247920]	Phase 4	510 participants (Actual)	Interventional	2017-11-04	Completed
The Effect of Rectal Swab Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy on Infectious Complications and Cost of Care: A Randomized Controlled Trial in the Netherlands. [NCT03228108]	Phase 4	1,538 participants (Actual)	Interventional	2018-04-03	Completed
A Multicenter, Randomized, Open Label Comparative Study Of Azithromycin Extended Release (ZMAX) Versus Amoxicillin/Clavulanate Potassium In Subjects With Acute Bacterial Sinusitis (ABS) In A Physician Practice Environment [NCT00367120]	Phase 4	762 participants (Actual)	Interventional	2006-06-30	Completed
Efficacy, Safety and Tolerability of Amoxicillin + Clavulanic Acid (875mg/125mg) Two Times a Day Compared to Clindamycin (150mg) Four Times a Day for 5-7 Days in Treatment of Acute Odontogenic Infection With or Without Abscess [NCT02141217]	Phase 4	472 participants (Actual)	Interventional	2013-03-21	Completed
Randomized Study Comparing Clinical and Microbiological Efficacy of Timentin Delivered Via Percutaneous Isolated Limb Perfusion (PILP) or Intravenous Infusion in Diabetic Subjects With Moderate to Severe Lower Limb Infection [NCT02158442]	Phase 2	15 participants (Actual)	Interventional	2013-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00377260 (24) [back to overview]	The Mean Number of Antibiotic Prescriptions, Exclusive of Study Medication, According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Mean Number of Visits to a Primary Care Provider (PCP) According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Mean Score Representing Parental Satisfaction With the Study Medication As Recorded at the End-of-therapy Visit According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Mean Score Representing Parental Satisfaction With the Study Medication As Recorded at the Follow-up Visit According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Mean Score Representing Parental Satisfaction With the Study Medication As Recorded at the On-therapy Visit According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Total Number of Visits, Summed Across All Participants, at Which a Family Member Reported Having Missed Work According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Total Number of Visits, Summed Across All Participants, at Which a Family Member Reported Making Special Daycare Arrangements According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Weighted Average Acute Otitis Media - Severity of Symptom (AOM-SOS) Score, According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Distribution of Children Developing Worsening Symptoms Prior to Receiving 72 Hours of Study Medication According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Distribution of Children With Nasopharyngeal (NP) Colonization With AOM Pathogens at the End-of-therapy Visit According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Distribution of Children With Nasopharyngeal (NP) Colonization With AOM Pathogens at the Follow-up Visit According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Distribution of Children With Nasopharyngeal (NP) Colonization With Penicillin-susceptible Streptococcus Pneumoniae (S. pn) at the End-of-therapy Visit According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Distribution of Children With Nasopharyngeal (NP) Colonization With Penicillin-susceptible Streptococcus Pneumoniae (S. pn) at the Follow-up Visit
NCT00377260 (24) [back to overview]	The Distribution of Children With Observed or Parent Reported Adverse Events or Complications According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Probability of Middle Ear Effusion, Based on an Algorithm That Estimates the Probability of Middle Ear Effusion From an Interpretable Tympanographic Configuration, at the Follow-up Visit According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Mean Number of Emergency Room Visits According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Probability of Middle Ear Effusion, Based on an Algorithm That Estimates the Probability of Middle Ear Effusion From an Interpretable Tympanographic Configuration, at the On-therapy Visit According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Time to Resolution of Symptoms, Defined as Acute Otitis Media-Severity of Symptoms (AOM-SOS) Score of 0 or 1 on Two Consecutive Occasions, According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Time to Resolution of Symptoms, Defined as Acute Otitis Media-Severity of Symptoms (AOM-SOS) Score of 0 or 1, According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Probability of Middle Ear Effusion, Based on an Algorithm That Estimates the Probability of Middle Ear Effusion From an Interpretable Tympanographic Configuration, at the End-of-therapy Visit According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Mean Acute Otitis Media - Severity of Symptom (AOM-SOS) Score, Post-enrollment, Over the First 7 Days of Therapy According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Mean Number of Times Analgesic Medication Was Administered to the Child According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Distribution of Clinical Failures by the On-therapy Visit According to Treatment Assignment
NCT00377260 (24) [back to overview]	The Distribution of Clinical Failures by the End-of-therapy Visit According to Treatment Assignment
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) at 3 to 5 Days After Start of Treatment in the Microbiological Valid (MBV) Population
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) After 7 - 21 Days of Treatment in the ITT Population With Causative Organisms
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the Microbiological Valid (MBV) Population
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the ITT Population With Causative Organisms
NCT00402727 (12) [back to overview]	Percentage of Participants Assessed as Resolution by the Data Review Committee (DRC) at End of Therapy in the Per Protocol (PP) Population
NCT00402727 (12) [back to overview]	Percentage of Participants Assessed as Resolution by the Data Review Committee (DRC) at End of Therapy in the Intent to Treat (ITT) Population
NCT00402727 (12) [back to overview]	Percentage of Participants Assessed as Improvements by the Data Review Committee (DRC) at the During Treatment Day 3-5 in the Per Protocol (PP) Population
NCT00402727 (12) [back to overview]	Percentage of Participants Assessed as Improvements by the Data Review Committee (DRC) at the During Treatment Day 3-5 in the Intent to Treat (ITT) Population
NCT00402727 (12) [back to overview]	Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population
NCT00402727 (12) [back to overview]	Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Intent to Treat (ITT) Population
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) at 3 to 5 Days After Start of Treatment in the ITT Population With Causative Organisms
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) After 7 - 21 Days of Treatment in the Microbiological Valid (MBV) Population
NCT00462020 (5) [back to overview]	Total Healthcare Visits
NCT00462020 (5) [back to overview]	Length of Stay After Operation
NCT00462020 (5) [back to overview]	Abscess After Appendectomy
NCT00462020 (5) [back to overview]	Operative Time
NCT00462020 (5) [back to overview]	Time to Regular Diet
NCT00493038 (5) [back to overview]	Number of Participants With Response (Microbiologically Valid Patients)
NCT00493038 (5) [back to overview]	Number of Participants With Response (Per-protocol Population)
NCT00493038 (5) [back to overview]	Number of Participants With Response (Microbiologically Valid Patients)
NCT00493038 (5) [back to overview]	Number of Participants With Response (Per-protocol Population)
NCT00493038 (5) [back to overview]	Number of Participants With Response (Intent-to-treat Population)
NCT00495586 (2) [back to overview]	Number of Patients Who Were Cured
NCT00495586 (2) [back to overview]	Number of Days Till the Next Exacerbation
NCT00797108 (8) [back to overview]	Number of Participants With Microbiological Response at Test of Cure (TOC) Visit
NCT00797108 (8) [back to overview]	Percentage of Participants With Clinical Response at End of Treatment (EOT) and Follow-up Visit
NCT00797108 (8) [back to overview]	Number of Participants With Abnormal Physical Examination Findings
NCT00797108 (8) [back to overview]	Percentage of Participants With Clinical Response at Test of Cure (TOC) Visit
NCT00797108 (8) [back to overview]	Number of Participants Who Died
NCT00797108 (8) [back to overview]	Number of Participants With Abnormal Laboratory Test Findings
NCT00797108 (8) [back to overview]	Change From Baseline in Community Acquired Pneumonia (CAP) Symptom Questionnaire at Test of Cure (TOC) and Follow-up Visit
NCT00797108 (8) [back to overview]	Number of Participants With Categorical Change From Baseline in Vital Signs
NCT00801099 (1) [back to overview]	Number of Participants With Surgical Site Infections
NCT00835705 (6) [back to overview]	AUC0-inf - [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Amoxicillin
NCT00835705 (6) [back to overview]	AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Clavulanic Acid
NCT00835705 (6) [back to overview]	AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Amoxicillin
NCT00835705 (6) [back to overview]	AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Clavulanic Acid
NCT00835705 (6) [back to overview]	Cmax (Maximum Observed Concentration) - Clavulanic Acid
NCT00835705 (6) [back to overview]	Cmax (Maximum Observed Concentration) - Amoxicillin
NCT00836901 (6) [back to overview]	AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Clavulanic Acid
NCT00836901 (6) [back to overview]	AUC0-t - [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Amoxicillin
NCT00836901 (6) [back to overview]	AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Clavunlanic Acid
NCT00836901 (6) [back to overview]	AUC0-inf - [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Amoxicillin
NCT00836901 (6) [back to overview]	Cmax (Maximum Observed Concentration) - Clavulanic Acid
NCT00836901 (6) [back to overview]	Cmax (Maximum Observed Concentration) - Amoxicillin
NCT00840099 (6) [back to overview]	Bioequivalence Based on Cmax for Amoxicillin
NCT00840099 (6) [back to overview]	Bioequivalence Based on AUC0-inf for Amoxicillin
NCT00840099 (6) [back to overview]	Bioequivalence Based on AUC0-inf for Clavulanic Acid
NCT00840099 (6) [back to overview]	Bioequivalence Based on AUC0-t for Amoxicillin
NCT00840099 (6) [back to overview]	Bioequivalence Based on AUC0-t for Clavulanic Acid
NCT00840099 (6) [back to overview]	Bioequivalence Based on Cmax for Clavulanic Acid
NCT00840840 (6) [back to overview]	Bioequivalence Based on Cmax for Clavulanic Acid
NCT00840840 (6) [back to overview]	Bioequivalence Based on AUC0-inf for Amoxicillin
NCT00840840 (6) [back to overview]	Bioequivalence Based on AUC0-inf for Clavulanic Acid
NCT00840840 (6) [back to overview]	Bioequivalence Based on Cmax for Amoxicillin
NCT00840840 (6) [back to overview]	Bioequivalence Based on AUC0-t for Clavulanic Acid
NCT00840840 (6) [back to overview]	Bioequivalence Based on AUC0-t for Amoxicillin
NCT01069900 (20) [back to overview]	Corrected QT (QTc) Interval Calculated (Calc) Bazett Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	Corrected QT (QTc) Interval Calculated (Calc) Fridericia Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	Heart Rate Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	Incidence Rates of Musculoskeletal Adverse Events by Primary System Organ Class (SOC) and Preferred Term
NCT01069900 (20) [back to overview]	Number of Subjects With Clinical Cardiac Adverse Events
NCT01069900 (20) [back to overview]	Clinical Response at Test-of-Cure (TOC) Visit in Subjects With Bacteriologically Confirmed Complicated Intra-abdominal Infection (cIAI)
NCT01069900 (20) [back to overview]	Bacteriological Response at a 'During Therapy' Visit
NCT01069900 (20) [back to overview]	Bacteriological Response at Test-of-Cure (TOC) Visit
NCT01069900 (20) [back to overview]	Bacteriological Response at the End of Treatment (EOT) Visit
NCT01069900 (20) [back to overview]	Clinical Response at a 'During Therapy' Visit
NCT01069900 (20) [back to overview]	Clinical Response at Test-of-Cure (TOC) Visit
NCT01069900 (20) [back to overview]	Number of Subjects With Adverse Events
NCT01069900 (20) [back to overview]	Number of Subjects With Musculoskeletal Adverse Events
NCT01069900 (20) [back to overview]	Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Calc Bazett Correction on Treatment Day 1 and During Therapy Day 3
NCT01069900 (20) [back to overview]	Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Interval Calc Fridericia Correction on Treatment Day 1 and During Therapy Day 3
NCT01069900 (20) [back to overview]	PR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	Clinical Response at the End-of-Treatment (EOT) Visit
NCT01069900 (20) [back to overview]	QRS Interval Changes in Electrocardiogram (ECG) Profiles From Predose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	QT Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	RR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01110382 (7) [back to overview]	The Number of Participants With Favorable Per-participant Microbiological Response
NCT01110382 (7) [back to overview]	Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at Test Of Cure (TOC) Visit
NCT01110382 (7) [back to overview]	Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at Late Follow-Up (LFU) Visit
NCT01110382 (7) [back to overview]	The Number of Participants With Clinical Improvement Rate at End of IV (EIV) Visit
NCT01110382 (7) [back to overview]	The Number of Participants With Clinical Cure Rate at Test Of Cure (TOC) Visit
NCT01110382 (7) [back to overview]	The Number of Participants With Clinical Cure Rate at Late Follow-Up (LFU) Visit
NCT01110382 (7) [back to overview]	Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at End of IV (EIV) Visit
NCT01110408 (7) [back to overview]	The Number of Participants With Favorable Per-participant Microbiological Response
NCT01110408 (7) [back to overview]	The Number of Participants With Clinical Cure Rate at Test Of Cure (TOC) Visit
NCT01110408 (7) [back to overview]	The Number of Participants With Clinical Improvement Rate at End of IV (EIV) Visit
NCT01110408 (7) [back to overview]	Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at End of IV (EIV) Visit
NCT01110408 (7) [back to overview]	Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at Test Of Cure (TOC) Visit
NCT01110408 (7) [back to overview]	Number of Participants With Sustained Favorable Per-pathogen Microbiological Outcome Rate at Late Follow-Up (LFU) Visit
NCT01110408 (7) [back to overview]	The Number of Participants With Clinical Cure Rate at Late Follow-Up (LFU) Visit
NCT01110421 (7) [back to overview]	The Number of Participants With Favorable Per-participant Microbiological Response Rate
NCT01110421 (7) [back to overview]	The Number of Participants With Clinical Cure Rate at Late Follow-Up (LFU) Visit
NCT01110421 (7) [back to overview]	The Number of Participants With Clinical Cure Rate at Test Of Cure (TOC) Visit
NCT01110421 (7) [back to overview]	The Number of Participants With Clinical Improvement Rate at End of IV (EIV) Visit
NCT01110421 (7) [back to overview]	Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at End of IV (EIV) Visit
NCT01110421 (7) [back to overview]	Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at Test Of Cure (TOC) Visit
NCT01110421 (7) [back to overview]	Number of Participants With Sustained Favorable Per-pathogen Microbiological Outcome Rate at Late Follow-Up (LFU) Visit
NCT01125098 (1) [back to overview]	To Evaluate the Rate of Severe Exacerbations in COPD, Comparing COPD Patients Previously Treated According to the PRO-CT Protocol Versus COPD Patients Previously Treated With Standard Antibiotic Therapy.
NCT01166945 (2) [back to overview]	Percentage of Participants With Antibiotic Resistant Flora on Day 30 Compared to Baseline
NCT01166945 (2) [back to overview]	Proportion of Children With Clinical Relapse on Day 10 (Short Course) vs Day 20 (Long Course)
NCT01473368 (6) [back to overview]	Gastrointestinal Symptom Rating Scale
NCT01473368 (6) [back to overview]	Gastrointestinal Symptoms Response Scale
NCT01473368 (6) [back to overview]	Gastrointestinal Symptoms Response Score
NCT01473368 (6) [back to overview]	Operational Taxonomic Units
NCT01473368 (6) [back to overview]	Prevalence of Escherichia in Stool
NCT01473368 (6) [back to overview]	Gastrointestinal Symptom Rating Scale
NCT01511107 (22) [back to overview]	The Distribution of AOM Recurrences With a Nasopharyngeal (NP) Culture at Onset That is Positive Only for One or More Susceptible Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen
NCT01511107 (22) [back to overview]	The Mean Rate, Per Month, of Protocol AOM Recurrences and Relapses Within 60 Days of Enrollment
NCT01511107 (22) [back to overview]	The Distribution of AOM Recurrences With a Nasopharyngeal (NP) Culture at Onset That is Positive for One or More Nonsusceptible Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen
NCT01511107 (22) [back to overview]	The Distribution of AOM Recurrences With a Nasopharyngeal (NP) Culture at Onset That is Negative for AOM Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen
NCT01511107 (22) [back to overview]	The Distribution of Children Whose Nasopharyngeal (NP) Isolates at Enrollment Are Pathogen Negative or Positive Only for at Least One Susceptible Pathogen Who Become Colonized With Nonsusceptible Pathogens at Any Time Over the Course of Follow-up
NCT01511107 (22) [back to overview]	The Distribution of Children for Whom Diaper Dermatitis Was Reported and Associated With Study Product
NCT01511107 (22) [back to overview]	The Distribution of Children for Whom the Follow-up Nasopharyngeal (NP) Culture at the Day 12-14 Visit, Specific to the Index Episode, Yields a Nonsusceptible Streptococcus Pneumoniae (S pn) Isolate
NCT01511107 (22) [back to overview]	The Distribution of Children for Whom the Follow-up Nasopharyngeal (NP) Culture at the Day 12-14 Visit, Specific to the Index Episode, Yields a Nonsusceptible Haemophilus Influenzae (H Flu) Isolate
NCT01511107 (22) [back to overview]	The Distribution of Children for Whom Protocol-Defined Diarrhea (PDD) Was Reported and Associated With Study Product
NCT01511107 (22) [back to overview]	The Distribution of AOM Recurrences Categorized as Treatment Failure (TF) at or Before the Day 12-14 End-of-Treatment Visit
NCT01511107 (22) [back to overview]	The Distribution of Children With a Nasopharyngeal (NP) Culture at Enrollment That is Positive for One or More Nonsusceptible Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen
NCT01511107 (22) [back to overview]	The Distribution of Children Categorized as Treatment Failure (TF) at or Before the Day 12-14 End-of-Treatment Visit Specific to the Index Episode of AOM
NCT01511107 (22) [back to overview]	The Distribution of Children With a Nasopharyngeal (NP) Culture at Enrollment That is Positive Only for One or More Susceptible Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen
NCT01511107 (22) [back to overview]	The Distribution of Children With AOM Recurrences and Relapses Within 60 Days of Enrollment
NCT01511107 (22) [back to overview]	The Distribution of Children With AOM Recurrences and Relapses Within the Entire Respiratory Season
NCT01511107 (22) [back to overview]	The Mean Acute Otitis Media - Severity of Symptom (AOM-SOS) Scores Days 6 to 14
NCT01511107 (22) [back to overview]	The Mean Number of Days Systemic Antibiotics Were Received During the Entire Respiratory Season
NCT01511107 (22) [back to overview]	The Distribution of AOM Recurrences for Which the Follow-up Nasopharyngeal (NP) Culture at the Day 12-14 Visit Yields a Nonsusceptible Streptococcus Pneumoniae (S pn) Isolate
NCT01511107 (22) [back to overview]	The Distribution of AOM Recurrences for Which the Follow-up Nasopharyngeal (NP) Culture at the Day 12-14 Visit Yields a Nonsusceptible Haemophilus Influenzae (H Flu) Isolate
NCT01511107 (22) [back to overview]	The Distribution of 6 Week Follow-up, Non-Illness Visits During the Respiratory Season at Which a Nonsusceptible Pathogen is Recovered
NCT01511107 (22) [back to overview]	The Mean Rate, Per Month, of Protocol AOM Recurrences and Relapses Within the Entire Respiratory Season
NCT01511107 (22) [back to overview]	The Distribution of Children With a Nasopharyngeal (NP) Culture at Enrollment That is Negative for AOM Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen
NCT01561703 (1) [back to overview]	Healthcare Utilization
NCT01575899 (3) [back to overview]	Eradication Rate (Participants Naive to Anti-H. Pylori Treatment)
NCT01575899 (3) [back to overview]	Eradication Rate of Participants Living in Rural Area.
NCT01575899 (3) [back to overview]	Re-eradication Rate
NCT01919411 (6) [back to overview]	Lund Kennedy Endoscopic Score
NCT01919411 (6) [back to overview]	Number of Participants With Post Operative Infection
NCT01919411 (6) [back to overview]	Number of Participants With Post Operative Infection
NCT01919411 (6) [back to overview]	Sinonasal Outcome Test - 22
NCT01919411 (6) [back to overview]	Lund Kennedy Endoscopic Score
NCT01919411 (6) [back to overview]	Sinonasal Outcome Test - 22
NCT01934231 (6) [back to overview]	"Number of Participants With a Clinical Outcome of Cure at Both the End of Treatment and Test of Cure (EOT and TOC: Day 8 and Day 15)"
NCT01934231 (6) [back to overview]	"Number of Participants With a Clinical Outcome of Cure at Test of Cure (TOC: Day 15)"
NCT01934231 (6) [back to overview]	"Number of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT: Day 8)"
NCT01934231 (6) [back to overview]	Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Participant at EOT (Day 8)
NCT01934231 (6) [back to overview]	Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8
NCT01934231 (6) [back to overview]	Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15
NCT02141217 (5) [back to overview]	Number of Participants (Par.) Achieving Clinical Success (CS) (Cure or Improvement [Imp] in Signs [s] and Symptoms [sx] [s/sx]) Without Considering Clinical (cl) Judgment (Jdg) of the Investigator (Inv) at Day 5
NCT02141217 (5) [back to overview]	Number of Participants Achieving Clinical Success (Cure or Improvement) Considering Clinical Judgment of the Investigator at Day 5
NCT02141217 (5) [back to overview]	Percentage of Participants Achieving Clinical Success (Cure or Improvement) Considering Clinical Judgment of the Investigator at the End of Treatment (Day 5 or Day 7)
NCT02141217 (5) [back to overview]	Change From Baseline in the Visual Analogue Scale Assessment of Pain Score at Days 2, 5 and 7
NCT02141217 (5) [back to overview]	Change From Baseline in Visual Analogue Scale Assessment of Swelling at Days 2, 5 and 7
NCT02158442 (1) [back to overview]	Efficacy of Timentin Delivered by PILP Procedure (Treatment Group) Versus Intravenous Delivery (Control Group) at Reducing Microbiological Load in Subjects With Diabetes, and Significant Wound Infection of the Lower Limb.
NCT02340000 (6) [back to overview]	Willingness to Take the Study Antibiotic in the Future
NCT02340000 (6) [back to overview]	Nasal Colonization With Resistant Bacteria
NCT02340000 (6) [back to overview]	SNOT-16 - Day 10
NCT02340000 (6) [back to overview]	SNOT-16 - Day 3
NCT02340000 (6) [back to overview]	Subjective Improvement - Day 10
NCT02340000 (6) [back to overview]	"Subjective Improvement - Day 3 (Rating of a Lot Better or no Symptoms)"
NCT02554383 (8) [back to overview]	The Distribution of Children Experiencing Treatment Failure (TF)
NCT02554383 (8) [back to overview]	The Mean Pediatric Rhinosinusitis Symptom Scale (PRSS) Score Over the First 10 Days of Follow-up According to the Presence of Pathogens in the Nasopharynx at Enrollment
NCT02554383 (8) [back to overview]	The Distribution of Children Compliant With Study Medication
NCT02554383 (8) [back to overview]	The Mean Pediatric Rhinosinusitis Symptom Scale (PRSS) Score Over the First 10 Days of Follow-up According to the Presence of Colored Nasal Discharge at Enrollment
NCT02554383 (8) [back to overview]	The Distribution of Children With a Nonsusceptible Pathogen at the Follow-up Visit
NCT02554383 (8) [back to overview]	The Distribution of Children Receiving a Systemic Antibiotic Over the First 10 Days of Follow-up
NCT02554383 (8) [back to overview]	The Distribution of Children for Whom Diarrhea or Generalized Rash Was Reported
NCT02554383 (8) [back to overview]	The Distribution of Children Developing Acute Otitis Media (AOM) Over the First 10 Days of Follow-up
NCT02563769 (8) [back to overview]	Changes in Blood Pressure in Response to IV Cocaine With and Without CLAV Dosing
NCT02563769 (8) [back to overview]	Change in Heart Rate in Response to IV Cocaine Infusion With and Without CLAV Dosing
NCT02563769 (8) [back to overview]	Pharmacokinetic (PK) Parameter of Cocaine-concentration
NCT02563769 (8) [back to overview]	Number of Participants With Severe Adverse Events (AEs)
NCT02563769 (8) [back to overview]	Electrocardiogram (ECG) Following IV Cocaine With and Without CLAV Dosing
NCT02563769 (8) [back to overview]	Difference in CLAV Concentrations Between the 250mg and 500mg CLAV Doses
NCT02563769 (8) [back to overview]	Clavulanic Acid (CLAV) Concentrations Following CLAV 250mg and CLAV 500mg Doses
NCT02563769 (8) [back to overview]	Pupil Pharmacodynamic Effects of Cocaine With Clavulanic Acid
NCT02567825 (12) [back to overview]	The Distribution of Children With a Penicillin-Nonsusceptible Nasopharyngeal or Throat Isolate At Any Follow-up Visit According to the Colonization Status at Enrollment
NCT02567825 (12) [back to overview]	The Rate of Occurrence of Acute Otitis Media (AOM) Episodes Per Child-Year According to the Estimated Risk of Acute Otitis Media (AOM) Recurrences at Enrollment
NCT02567825 (12) [back to overview]	The Mean Scores on the 6 Item Quality of Life Survey Questionnaire (OM-6)
NCT02567825 (12) [back to overview]	The Mean Scores on the 6 Item Caregiver Impact Questionnaire (CIQ)
NCT02567825 (12) [back to overview]	The Mean Days Per Year Children Experience AOM Symptoms With an Intact Tympanic Membrane (TM)
NCT02567825 (12) [back to overview]	The Mean Days Per Year Children Experience Tube Otorrhea
NCT02567825 (12) [back to overview]	The Mean Days Per Year Children Receive Systemic Antimicrobials for AOM
NCT02567825 (12) [back to overview]	The Mean Score Representing Parental Satisfaction With Clinical Management
NCT02567825 (12) [back to overview]	The Rate of Occurrence of Acute Otitis Media (AOM) Episodes Per Child-Year
NCT02567825 (12) [back to overview]	The Total Cost of Management of Recurrent Acute Otitis Media Per Quality Adjusted Life Days (QALDs) as a Measure of Cost-Effectiveness
NCT02567825 (12) [back to overview]	The Time to the First Episode of AOM
NCT02567825 (12) [back to overview]	The Total Cost of Management of Recurrent Acute Otitis Media Per Quality Adjusted Life Days (QALDs) as a Measure of Cost-Effectiveness According to the Estimated Risk of Acute Otitis Media Recurrences at Enrollment
NCT02605122 (4) [back to overview]	Summary of Clinical Cure
NCT02605122 (4) [back to overview]	Overview of Adverse Events By Treatment Arm
NCT02605122 (4) [back to overview]	Summary of Early Clinical Response
NCT02605122 (4) [back to overview]	Summary of Clinical Improvement
NCT02630992 (11) [back to overview]	Distribution of Population Plasma Concentration of Amoxicillin According to Time For Participants Receiving Formulation 2
NCT02630992 (11) [back to overview]	Distribution of Population Plasma Concentration of Clavulanate According to Time For Participants Receiving Formulation 1
NCT02630992 (11) [back to overview]	Distribution of Population Plasma Concentration of Clavulanate According to Time For Participants Receiving Formulation 2
NCT02630992 (11) [back to overview]	The Distribution of Participants Receiving Formulation 1 for Whom Diaper Dermatitis Was Reported and Associated With Study Product
NCT02630992 (11) [back to overview]	The Distribution of Participants Receiving Formulation 1 for Whom Protocol-Defined Diarrhea (PDD) Was Reported and Associated With Study Product
NCT02630992 (11) [back to overview]	The Distribution of Participants Receiving Formulation 2 Categorized as Treatment Failure (TF) at or Before the End-of-Treatment Visit
NCT02630992 (11) [back to overview]	The Distribution of Participants Receiving Formulation 2 for Whom Diaper Dermatitis Was Reported and Associated With Study Product
NCT02630992 (11) [back to overview]	The Distribution of Participants Receiving Formulation 2 for Whom Protocol-Defined Diarrhea (PDD) Was Reported and Associated With Study Product
NCT02630992 (11) [back to overview]	The Mean Score Representing the Parent or Guardian's Level of Satisfaction With Therapy for Participants Receiving Formulation 1
NCT02630992 (11) [back to overview]	The Mean Score Representing the Parent or Guardian's Level of Satisfaction With Therapy for Participants Receiving Formulation 2
NCT02630992 (11) [back to overview]	Distribution of Population Plasma Concentration of Amoxicillin According to Time For Participants Receiving Formulation 1
NCT02724410 (4) [back to overview]	Number of Participants With Wound Infections
NCT02724410 (4) [back to overview]	Number Participants With Readmission Within 30 Days
NCT02724410 (4) [back to overview]	Number of Participants With Postoperative Abscess
NCT02724410 (4) [back to overview]	Hospital Charge
NCT02800785 (8) [back to overview]	Days in Hospital After Index Treatment Within 90 Days
NCT02800785 (8) [back to overview]	Rates of Participants With Appendiceal Cancer
NCT02800785 (8) [back to overview]	Eventual Appendectomy Incidence Proportion
NCT02800785 (8) [back to overview]	Number of Clinic Visits or Emergency Room Visits
NCT02800785 (8) [back to overview]	Total Number of Patients Who Had Resolution of Appendicitis Symptoms at 30 Days
NCT02800785 (8) [back to overview]	Rate of Participants With Perforated Appendicitis
NCT02800785 (8) [back to overview]	Patient-reported Quality of Life as Measured by EuroQol (EQ-5D)
NCT02800785 (8) [back to overview]	Number of Participants With at Least One Complications From Treatment
NCT02891915 (10) [back to overview]	Resolution of Symptoms (a Component of DOOR)
NCT02891915 (10) [back to overview]	Number of Participants Receiving Non-study Systemic Antibiotics for Persistent or Worsening Pneumonia During Medically Attended Visits
NCT02891915 (10) [back to overview]	Number of Participants Receiving Non-study Systemic Antibiotics for All Causes During Medically Attended Visits
NCT02891915 (10) [back to overview]	Adequate Clinical Response Rates (a Component of DOOR)
NCT02891915 (10) [back to overview]	Adequate Clinical Response Rates (a Component of DOOR)
NCT02891915 (10) [back to overview]	Number of Participants Receiving Non-study Systemic Antibiotics for All Causes During Medically Attended Visits
NCT02891915 (10) [back to overview]	Resolution of Symptoms (a Component of DOOR)
NCT02891915 (10) [back to overview]	Number of Participants Reporting Solicited Symptoms
NCT02891915 (10) [back to overview]	Number of Participants Reporting Solicited Symptoms
NCT02891915 (10) [back to overview]	Number of Participants Receiving Non-study Systemic Antibiotics for Persistent or Worsening Pneumonia During Medically Attended Visits
NCT03174184 (5) [back to overview]	Estimate the Antimycobacterial Activity Based on Liquid Culture Time-to-positivity
NCT03174184 (5) [back to overview]	Estimate of the 14-day Early Bactericidal Activity (EBA), Based on Colony Forming Unit Counts, of the Combination of Meropenem and Amoxicillin/Clavulanate, Without Versus With Rifampin
NCT03174184 (5) [back to overview]	Distribution of Minimum Inhibitory Concentration (MIC) of Rifampin
NCT03174184 (5) [back to overview]	AUC for Rifampin
NCT03174184 (5) [back to overview]	Frequency of Grade 2 or Higher Adverse Events
NCT03357614 (2) [back to overview]	Percentage of Participants With Microbiologic Success
NCT03357614 (2) [back to overview]	Percentage of Participants With Overall Success
NCT03358576 (2) [back to overview]	Percentage of Participants With Clinical Success
NCT03358576 (2) [back to overview]	Percentage of Participants With Clinical Success
NCT03755765 (5) [back to overview]	Level of Fecal SCFA Butyrate
NCT03755765 (5) [back to overview]	Level of Fecal SCFA Propionate
NCT03755765 (5) [back to overview]	Level of Fecal Short-chain Fatty Acid (SCFA) Acetate
NCT03755765 (5) [back to overview]	Change in Community Diversity (Shannon Diversity Index) From Post run-in Baseline
NCT03755765 (5) [back to overview]	Change in Community Diversity (Shannon Diversity Index) From Pre run-in Baseline
NCT03818815 (3) [back to overview]	Evaluation of Efficacy (Otoscopy)
NCT03818815 (3) [back to overview]	Number of Participants With Adverse Events
NCT03818815 (3) [back to overview]	Evaluation of Efficacy (Otoscopy)
NCT04411914 (5) [back to overview]	Changes in Resting State Network Connectivity From Baseline
NCT04411914 (5) [back to overview]	Change in Brain Glutamine From Baseline
NCT04411914 (5) [back to overview]	Brain Glutamate Concentration in the Anterior Cingulate Cortex (ACC) in Subjects With Cocaine Use Disorder (CUD) Treated With Escalating Doses of Clavulanate (CLAV)
NCT04411914 (5) [back to overview]	Number of Participants With Treatment-related Adverse Events (AEs)
NCT04411914 (5) [back to overview]	Craving

The Mean Number of Antibiotic Prescriptions, Exclusive of Study Medication, According to Treatment Assignment

This is the number of times, in the course of the study, a child required treatment with an antibiotic other than the blinded study medication. (NCT00377260)
Timeframe: This was assessed at each study visit, i.e. Day 4-5, Day 10-12, Day 21-25, and at interim visits. The last assessment was made at the Day 21-25 visit. The mean day for this latter visit was 22.8.

Intervention	antibiotic prescriptions (Mean)
Amoxicillin-Clavulanate	.35
Placebo	.75

Intervention	Participants (Number)
	Number of children with worsening symptoms	Number of children unchanged or improved
Amoxicillin-Clavulanate	31	112
Placebo	39	104

Intervention	participants (Number)
	Presence of at least one AOM pathogen	Absence of any AOM pathogen	Presence of Streptococcus pneumoniae	Absence of Streptococcus pneumoniae	Presence of Haemophilus influenzae	Absence of Haemophilus influenzae	Presence of Moraxella catarrhalis	Absence of Moraxella catarrhalis	Presence of Streptococcus pyogenes	Absence of Streptococcus pyogenes
Amoxicillin-Clavulanate	63	67	18	112	45	85	9	121	0	130
Placebo	88	43	46	85	44	87	38	93	3	128

Intervention	participants (Number)
	Colonization with penicillin-susceptible S. pn	No colonization with penicillin-susceptible S. pn
Amoxicillin-Clavulanate	1	129
Placebo	28	102

Intervention	participants (Number)
	Mastoiditis	Perforation of tympanic membrane	Protocol-defined diarrhea	Diaper dermatitis	Oral thrush	Vomiting	Rash
Amoxicillin-Clavulanate	0	1	36	73	7	12	1
Placebo	1	7	22	51	1	12	2

Intervention	participants (Number)
	Resolved by Day 1 - PM	Censored by Day 1 - PM	Resolved by Day 2 - AM	Censored by Day 2 - AM	Resolved by Day 2 - PM	Censored by Day 2 - PM	Resolved by Day 3 - AM	Censored by Day 3 - AM	Resolved by Day 3 - PM	Censored by Day 3 - PM	Resolved by Day 4	Censored by Day 4	Resolved by Day 5	Censored by Day 5	Resolved by Day 6	Censored by Day 6	Resolved by Day 7	Censored by Day 7
Amoxicillin-Clavulanate	0	1	17	1	29	1	34	1	50	1	58	1	70	1	80	1	96	48
Placebo	0	2	8	2	20	3	29	3	42	4	51	5	63	5	69	5	76	71

Intervention	AOM-SOS score (Mean)
	Day 1 PM	Day 2 AM	Day 2 PM	Day 3 AM	Day 3 PM	Day 4	Day 5	Day 6	Day 7
Amoxicillin-Clavulanate	5.80	4.12	3.78	2.86	2.82	2.40	1.93	1.40	1.28
Placebo	6.20	4.85	4.33	3.37	3.25	2.68	2.41	2.31	1.94

Intervention	participants (Number)
	Clinical failures by the on therapy visit	Subjects not classified as clinical failures
Amoxicillin-Clavulanate	5	138
Placebo	34	111

Intervention	participants (Number)
	Clinical failures by the end of therapy visit	Subjects not classified as clinical failures
Amoxicillin-Clavulanate	23	119
Placebo	73	70

Intervention	Participants (Number)
	Bacteriological success	Failure
Amoxicillin/Clavulanate	25	1
Moxifloxacin (Avelox, BAY12-8039)	21	0

Intervention	Participants (Number)
	Bacteriological success	Failure	Missing / Indeterminate
Amoxicillin/Clavulanate	23	0	3
Moxifloxacin (Avelox, BAY12-8039)	19	0	2

Intervention	visits to PCP (Mean)
Amoxicillin-Clavulanate	.15
Placebo	.23

Intervention	probability of effusion (Mean)
	Right ear	Left ear
Amoxicillin-Clavulanate	.28	.27
Placebo	.32	.37

Intervention	probability of effusion (Mean)
	Right ear	Left ear
Amoxicillin-Clavulanate	.36	.39
Placebo	.42	.48

Intervention	probability of effusion (Mean)
	Right ear	Left ear
Amoxicillin-Clavulanate	.32	.33
Placebo	.41	.41

Intervention	participants (Number)
	Eradication	Persistence	Not Applicable
Ceftriaxone and Amoxicillin/Clavulanate	3	0	1
Sulopenem (Multi Intravenous Dose) and PF-03709270	4	0	1
Sulopenem (Single Intravenous Dose) and PF-03709270	4	0	0

Intervention	percentage of participants (Number)
	EOT: Cure	EOT: Improvement	EOT: Failure	Follow-up: Cure	Follow-up: Failure	Follow-up: Indeterminate
Ceftriaxone and Amoxicillin/Clavulanate	75.0	12.5	12.5	62.5	12.5	25.0
Sulopenem (Multi Intravenous Dose) and PF-03709270	75.0	25.0	0.0	87.5	0.0	12.5
Sulopenem (Single Intravenous Dose) and PF-03709270	60.0	30.0	10.0	90.0	0.0	10.0

Intervention	percentage of participants (Number)
	Cure	Failure	Indeterminate
Ceftriaxone and Amoxicillin/Clavulanate	62.5	25.0	12.5
Sulopenem (Multi Intravenous Dose) and PF-03709270	87.5	12.5	0
Sulopenem (Single Intravenous Dose) and PF-03709270	90.0	10.0	0

Intervention	units on a scale (Mean)
	Baseline (n=10, 8, 8)	Change at TOC (n=9, 7, 6)	Change at Follow-up Visit (n=10, 8, 8)
Ceftriaxone and Amoxicillin/Clavulanate	2.57	-1.74	-1.52
Sulopenem (Multi Intravenous Dose) and PF-03709270	2.75	-2.02	-1.89
Sulopenem (Single Intravenous Dose) and PF-03709270	2.17	-1.43	-1.39

Intervention	participants (Number)
	Supine Systolic BP >=30 mmHg (n=3, 5, 4)	Sitting Systolic BP >=30 mmHg (n=7, 6, 6)	Supine Diastolic BP >=20 mmHg (n=3, 5, 4)	Sitting Diastolic BP >=20 mmHg (n=7, 6, 6)
Ceftriaxone and Amoxicillin/Clavulanate	1	1	2	0
Sulopenem (Multi Intravenous Dose) and PF-03709270	2	1	2	1
Sulopenem (Single Intravenous Dose) and PF-03709270	0	2	0	4

Intervention	milliseconds (Mean)
	Day 1: Pre-dose (N= 298, 150)	Change at Day 1 (N= 290, 148)	Day 3: Pre-dose (N= 292, 146)	Change at Day 3 (N= 287, 146)
Comparator Ertapenem	417.34	2.2905	412.7945	1
Moxifloxacin (Avelox, BAY12-8039)	419.5872	9.731	419.2055	9.2509

Intervention	Beats per minute (bpm) (Mean)
	Day 1: Pre-dose (N= 300, 150)	Change at Day 1 ((N= 294, 148)	Day 3: Pre-dose (N= 293, 146)	Change at Day 3 (N= 290, 146)
Comparator Ertapenem	90.4	0.3	82.6	-0.9
Moxifloxacin (Avelox, BAY12-8039)	93.4	2.8	84.3	1

Intervention	Percentage of subjects (Number)
	Forearm fracture	Joint injury	Ligament sprain	Muscle strain	Arthralgia	Joint swelling	Musculoskeletal pain	Myalgia
Comparator Ertapenem	0	0.7	0.7	0.7	1.3	0.7	0	0
Moxifloxacin (Avelox, BAY12-8039)	0.3	0	0.3	0	3	0	1	0.3

Intervention	Subjects (Number)
	Any AE	Any SAE
Comparator Ertapenem	7	0
Moxifloxacin (Avelox, BAY12-8039)	38	0

Intervention	Percentage of subjects (Number)
	Clinical Cure	Clinical Failure	Indeterminate
Comparator Ertapenem	95.3	2	2.7
Moxifloxacin (Avelox, BAY12-8039)	86.2	5.7	8.1

clavulanic acid

Description

Cross-References

Synonyms (71)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (1)

Protein Targets (37)

Inhibition Measurements

Other Measurements

Biological Processes (53)

Molecular Functions (28)

Ceullar Components (26)

Bioassays (302)

Research

Studies (1,689)

Study Types

Clinical Trials (172)

Trial Overview

Trial Outcomes

The Mean Number of Antibiotic Prescriptions, Exclusive of Study Medication, According to Treatment Assignment

The Mean Number of Visits to a Primary Care Provider (PCP) According to Treatment Assignment

The Mean Score Representing Parental Satisfaction With the Study Medication As Recorded at the End-of-therapy Visit According to Treatment Assignment

The Mean Score Representing Parental Satisfaction With the Study Medication As Recorded at the Follow-up Visit According to Treatment Assignment

The Mean Score Representing Parental Satisfaction With the Study Medication As Recorded at the On-therapy Visit According to Treatment Assignment

The Total Number of Visits, Summed Across All Participants, at Which a Family Member Reported Having Missed Work According to Treatment Assignment

The Total Number of Visits, Summed Across All Participants, at Which a Family Member Reported Making Special Daycare Arrangements According to Treatment Assignment

The Weighted Average Acute Otitis Media - Severity of Symptom (AOM-SOS) Score, According to Treatment Assignment

The Distribution of Children Developing Worsening Symptoms Prior to Receiving 72 Hours of Study Medication According to Treatment Assignment

The Distribution of Children With Nasopharyngeal (NP) Colonization With AOM Pathogens at the End-of-therapy Visit According to Treatment Assignment

The Distribution of Children With Nasopharyngeal (NP) Colonization With AOM Pathogens at the Follow-up Visit According to Treatment Assignment

The Distribution of Children With Nasopharyngeal (NP) Colonization With Penicillin-susceptible Streptococcus Pneumoniae (S. pn) at the End-of-therapy Visit According to Treatment Assignment

The Distribution of Children With Nasopharyngeal (NP) Colonization With Penicillin-susceptible Streptococcus Pneumoniae (S. pn) at the Follow-up Visit

The Distribution of Children With Observed or Parent Reported Adverse Events or Complications According to Treatment Assignment

The Probability of Middle Ear Effusion, Based on an Algorithm That Estimates the Probability of Middle Ear Effusion From an Interpretable Tympanographic Configuration, at the Follow-up Visit According to Treatment Assignment

The Mean Number of Emergency Room Visits According to Treatment Assignment

The Probability of Middle Ear Effusion, Based on an Algorithm That Estimates the Probability of Middle Ear Effusion From an Interpretable Tympanographic Configuration, at the On-therapy Visit According to Treatment Assignment

The Time to Resolution of Symptoms, Defined as Acute Otitis Media-Severity of Symptoms (AOM-SOS) Score of 0 or 1 on Two Consecutive Occasions, According to Treatment Assignment

The Time to Resolution of Symptoms, Defined as Acute Otitis Media-Severity of Symptoms (AOM-SOS) Score of 0 or 1, According to Treatment Assignment

The Probability of Middle Ear Effusion, Based on an Algorithm That Estimates the Probability of Middle Ear Effusion From an Interpretable Tympanographic Configuration, at the End-of-therapy Visit According to Treatment Assignment

The Mean Acute Otitis Media - Severity of Symptom (AOM-SOS) Score, Post-enrollment, Over the First 7 Days of Therapy According to Treatment Assignment

The Mean Number of Times Analgesic Medication Was Administered to the Child According to Treatment Assignment

The Distribution of Clinical Failures by the On-therapy Visit According to Treatment Assignment

The Distribution of Clinical Failures by the End-of-therapy Visit According to Treatment Assignment

Percentage of Participants With Bacteriological Success (BS) at 3 to 5 Days After Start of Treatment in the Microbiological Valid (MBV) Population

Percentage of Participants With Bacteriological Success (BS) After 7 - 21 Days of Treatment in the ITT Population With Causative Organisms

Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the Microbiological Valid (MBV) Population

Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the ITT Population With Causative Organisms

Percentage of Participants Assessed as Resolution by the Data Review Committee (DRC) at End of Therapy in the Per Protocol (PP) Population

Percentage of Participants Assessed as Resolution by the Data Review Committee (DRC) at End of Therapy in the Intent to Treat (ITT) Population

Percentage of Participants Assessed as Improvements by the Data Review Committee (DRC) at the During Treatment Day 3-5 in the Per Protocol (PP) Population

Percentage of Participants Assessed as Improvements by the Data Review Committee (DRC) at the During Treatment Day 3-5 in the Intent to Treat (ITT) Population

Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population

Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Intent to Treat (ITT) Population

Percentage of Participants With Bacteriological Success (BS) at 3 to 5 Days After Start of Treatment in the ITT Population With Causative Organisms

Percentage of Participants With Bacteriological Success (BS) After 7 - 21 Days of Treatment in the Microbiological Valid (MBV) Population

Total Healthcare Visits

Length of Stay After Operation

Abscess After Appendectomy

Operative Time

Time to Regular Diet

Number of Participants With Response (Microbiologically Valid Patients)

Number of Participants With Response (Per-protocol Population)

Number of Participants With Response (Microbiologically Valid Patients)

Number of Participants With Response (Per-protocol Population)

Number of Participants With Response (Intent-to-treat Population)

Number of Patients Who Were Cured

Number of Days Till the Next Exacerbation

Number of Participants With Microbiological Response at Test of Cure (TOC) Visit

Percentage of Participants With Clinical Response at End of Treatment (EOT) and Follow-up Visit

Number of Participants With Abnormal Physical Examination Findings

Percentage of Participants With Clinical Response at Test of Cure (TOC) Visit

Number of Participants Who Died

Number of Participants With Abnormal Laboratory Test Findings

Change From Baseline in Community Acquired Pneumonia (CAP) Symptom Questionnaire at Test of Cure (TOC) and Follow-up Visit

Intervention	Percentage of subjects (Number)
	Presumed Persistence	Presumed Eradication	Indeterminate
Comparator Ertapenem	0.7	97.8	1.5
Moxifloxacin (Avelox, BAY12-8039)	1.2	95.6	3.2

Intervention	Percentage of subjects (Number)
	Clinical Improvement	Clinical Failure	Indeterminate
Comparator Ertapenem	98	0.7	1.4
Moxifloxacin (Avelox, BAY12-8039)	94.3	1	4.7

Intervention	Percentage of subjects (Number)
	Day1: Pre-dose QTc Calc Bazett > ULN (N= 300, 150)	Day1: Post-dose QTc Calc Bazett > ULN (N= 297,148)	Day1: Post-dose >30 ms from pre-dose (N= 297,148)	Day1: Post-dose >60 ms from pre-dose (N= 297,148)	Day3: Pre-dose QTc Calc Bazett > ULN (N= 293, 146)	Day3: Post-dose QTc Calc Bazett > ULN (N= 291,148)	Day3: Post-dose >30 ms from pre-dose (N= 291,148)	Day3: Post-dose >60 ms from pre-dose (N= 291,148)
Comparator Ertapenem	2.7	4.1	0	0	1.4	3.4	2	0.7
Moxifloxacin (Avelox, BAY12-8039)	7.7	16.2	5.4	0	3.8	15.5	9.6	0.7

Intervention	Percentage of subjects (Number)
	Day1: Pre-dose QTcCalcFridericia>ULN (N= 300, 150)	Day1: Post-dose QTcCalcFridericia>ULN (N= 297,148)	Day1: Post-dose >30 ms from pre-dose (N= 297,148)	Day1: Post-dose >60 ms from pre-dose (N= 297,148)	Day3: Pre-dose QTcCalcFridericia>ULN (N= 293, 146)	Day3: Post-dose QTcCalcFridericia>ULN (N= 291,148)	Day3: Post-dose >30 ms from pre-dose (N= 291,148)	Day3: Post-dose >60 ms from pre-dose (N= 291,148)
Comparator Ertapenem	1.3	2	0	0	1.4	1.4	3.4	0.7
Moxifloxacin (Avelox, BAY12-8039)	0.7	3	2	0.3	1.4	9.6	17.9	1.7

Intervention	milliseconds (Mean)
	Day 1: Pre-dose (N= 299, 150)	Change at Day 1 ( N= 292, 148)	Day 3: Pre-dose (N= 293, 146)	Change at Day 3 (N= 289, 146)
Comparator Ertapenem	140.5933	-0.0203	139.5685	1.5616
Moxifloxacin (Avelox, BAY12-8039)	136.8294	0.7123	139.4915	1.5813

Intervention	Percentage of subjects (Number)
	Resolution	Clinical Failure	Indeterminate
Comparator Ertapenem	98	0.7	1.4
Moxifloxacin (Avelox, BAY12-8039)	92.2	4.6	3.2

Intervention	milliseconds (Mean)
	Day 1: Pre-dose (N= 300, 150)	Change at Day 1 (N= 294, 148)	Day 3: Pre-dose (N= 293, 146)	Change at Day 3 (N= 289, 146)
Comparator Ertapenem	88.8067	1.223	89.3904	0.2877
Moxifloxacin (Avelox, BAY12-8039)	89.0333	0.119	89.2423	0.2768

Intervention	participants (Number)
	Streptococcus anginosus (13, 0)	Escherichia coli (19, 8)	Bacteroides fragilis (11, 1)
Doripenem	9	15	9
Meropenem	NA	5	1

Intervention	Participants (Number)
	Staphylococcus aureus (3, 0)	Escherichia coli (22, 7)	Klebsiella oxytoca (1, 0)	Klebsiella pneumoniae (1, 1)
Cefepime	NA	7	NA	1
Doripenem	3	22	1	1

Intervention	Participants (Number)
	Staphylococcus aureus (1)	Streptococcus pneumoniae (1)	Klebsiella pneumoniae (1)
Doripenem	1	1	1